

**WORLD INTELLECTUAL PROPERTY ORGANIZATION**  
International Bureau



(51) International Patent Classification 6 : C07C 311/00		A2	(11) International Publication Number: WO 99/33793
			(43) International Publication Date: 8 July 1999 (08.07.99)
(21) International Application Number: PCT/US98/27424		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 23 December 1998 (23.12.98)			
(30) Priority Data: 60/068,889 24 December 1997 (24.12.97) US			
(71) Applicant (for all designated States except US): VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 130 Waverly Street, Cambridge, MA 02139-4242 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): HALE, Michael, R. [US/US]; 42 Sunset Road, Bedford, MA 01730 (US). TUNG, Roger, D. [US/US]; 54 Richfield Road, Arlington, MA 01274 (US). BAKER, Christopher, T. [US/US]; Apartment 5, 23 Judith Lane, Waltham, MA 02154 (US). SPALTENSTEIN, Andrew [US/US]; 4105 Brewster Drive, Raleigh, NC 27606 (US). FURFINE, Eric, Steven [US/US]; 4133 Livingstone Place, Durham, NC 27707 (US). KALDOR, Istvan [US/US]; 7 Bonham Court, Durham, NC 27703 (US). KAZMIERSKI, Wieslaw, Mieczyslaw [US/US]; 1221 Stone Creek Way, Raleigh, NC 27615 (US).		Published Without international search report and to be republished upon receipt of that report.	
(74) Agents: HALEY, James, F., Jr.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US) et al.			
(54) Title: PRODRUGS OF ASPARTYL PROTEASE INHIBITORS			
(57) Abstract  The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile <i>in vivo</i> generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PRODRUGS OF ASPARTYL PROTEASE INHIBITORS

5

TECHNICAL FIELD OF THE INVENTION

The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile *in vivo* generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.

20

BACKGROUND OF THE INVENTION

Aspartyl protease inhibitors are considered the most effective current drug in the fight against HIV infection. These inhibitors, however, require certain physicochemical properties in order to achieve good potency against the enzyme. One of these properties is high hydrophobicity. Unfortunately, this property results in poor aqueous solubility and low oral bioavailability.

30

United States Patent 5,585,397 describes a class of sulfonamide compounds that are inhibitors of the

aspartyl protease enzyme. These compounds illustrate the drawbacks concomitant to pharmaceutical compositions comprising hydrophobic aspartyl protease inhibitors. For example, VX-478 (4-amino-N-((2S,3S)-2-hydroxy-4-phenyl-2-((S)-tetrahydrofuran-3-yl-oxycarbonylamino)-butyl-N-isobutyl-benzenesulfonamide) is an aspartyl protease inhibitor disclosed in the '397 patent. In its mesylate salt form, VX-478 has a relatively low aqueous solubility. While the oral bioavailability of this inhibitor in a "solution" formulation is excellent, the dosage of VX-478 in this form is severely limited by the amount of liquid present in the particular liquid dosage form, e.g., encapsulated into a soft gelatin capsule. A higher aqueous solubility would increase drug load per unit dosage of VX-478,

Currently, the mesylate formulation of VX-478 produces an upper limit of 150 mg of VX-478 in each capsule. Given a therapeutic dose of 2400 mg/day of VX-478, this formulation would require a patient to consume 16 capsules per day. Such a high pill burden would likely result in poor patient compliance, thus producing sub-optimal therapeutic benefit of the drug. The high pill burden is also a deterrent to increasing the amount of the drug administered per day to a patient. Another drawback of the pill burden and the concomitant patient compliance problem is in the treatment of children infected with HIV.

Furthermore, these "solution" formulations, such as the mesylate formulation, are at a saturation solubility of VX-478. This creates the real potential of having the drug crystallize out of solution under various storage and/or shipping conditions. This, in turn, would likely result in a loss of some of the oral bioavailability achieved with VX-478.

One way of overcoming these problems is to develop a standard solid dosage form, such as a tablet or a capsule or a suspension form. Unfortunately, such solid dosage forms have much lower oral bioavailability of the drug.


Thus, there is a need to improve the drug load per unit dosage form for aspartyl protease inhibitors. Such an improved dosage form would reduce the pill burden and increase patient compliance. It would also provide for the possibility of increasing the amounts of the drug administered per day to a patient.

#### SUMMARY OF THE INVENTION

The present invention provides novel prodrugs of a class of sulfonamide compounds that are inhibitors of aspartyl protease, in particular, HIV aspartyl protease. These prodrugs are characterized by high aqueous solubility, increased bioavailability and are readily metabolized into the active inhibitors *in vivo*. The present invention also provides pharmaceutical compositions comprising these prodrugs and methods of treating HIV infection in mammals using these prodrugs and the pharmaceutical compositions thereof.

These prodrugs can be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, antibiotics, immunomodulators or vaccines, for the treatment or prophylaxis of viral infection.

It is a principal object of this invention to provide novel prodrugs of a class of sulfonamides which are aspartyl protease inhibitors, and particularly, HIV aspartyl protease inhibitors. This novel class of sulfonamides is represented by formula I:



(I)

wherein:

- 5 each R<sup>1</sup> is independently selected from the group consisting of C(O)-, -S(O)<sub>2</sub>-, -C(O)-C(O)-, -O-C(O)-, -O-S(O)<sub>2</sub>, -NR<sup>2</sup>-S(O)<sub>2</sub>-, -NR<sup>2</sup>-C(O)- and -NR<sup>2</sup>-C(O)-C(O)-;
- each A is independently selected from the group consisting of 5-7 membered monocyclic heterocycles
- 10 containing from 1-3 endocyclic heteroatoms, which may be optionally methylated at the point of attachment, optionally benzofused, optionally attached through a C<sub>1</sub>-C<sub>3</sub> alkyl linker and optionally fused with a 5-7 membered monocyclic heterocycle containing from 1-2 endocyclic
- 15 heteroatoms, and wherein unmethylated THF is expressly excluded;
- each Ht is independently selected from C<sub>3</sub>-C<sub>7</sub> cycloalkyl; C<sub>5</sub>-C<sub>7</sub> cycloalkenyl; C<sub>6</sub>-C<sub>10</sub> aryl; or a 5-7 membered saturated or unsaturated heterocycle, containing
- 20 one or more heteroatoms selected from N, N(R<sup>2</sup>), O, S and S(O)<sub>n</sub>; wherein said aryl or said heterocycle is optionally fused to Q; and wherein any member of said Ht is optionally substituted with one or more substituents independently selected from oxo, -OR<sup>2</sup>, SR<sup>2</sup>, -R<sup>2</sup>, -
- 25 N(R<sup>2</sup>)(R<sup>2</sup>), -R<sup>2</sup>-OH, -CN, -CO<sub>2</sub>R<sup>2</sup>, -C(O)-N(R<sup>2</sup>)<sub>2</sub>, -S(O)<sub>2</sub>-N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)-C(O)-R<sup>2</sup>, -C(O)-R<sup>2</sup>, -S(O)<sub>n</sub>-R<sup>2</sup>, -OCF<sub>3</sub>, -S(O)<sub>n</sub>-Q, methylenedioxy, -N(R<sup>2</sup>)-S(O)<sub>2</sub>(R<sup>2</sup>), halo, -CF<sub>3</sub>, -NO<sub>2</sub>, Q, -OQ, -OR<sup>7</sup>, -SR<sup>7</sup>, -R<sup>7</sup>, -N(R<sup>2</sup>)(R<sup>7</sup>) or -N(R<sup>7</sup>)<sub>2</sub>;

- each Q is independently selected from a 3-7 membered saturated, partially saturated or unsaturated carbocyclic ring system; or a 5-7 membered saturated, partially saturated or unsaturated heterocyclic ring
- 5 containing one or more heteroatoms selected from O, N, S, S(O)<sub>n</sub> or N(R<sup>2</sup>); wherein Q is optionally substituted with one or more groups selected from oxo, -OR<sup>2</sup>, -R<sup>2</sup>, -N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)-C(O)-R<sup>2</sup>, -R<sup>2</sup>-OH, -CN, -CO<sub>2</sub>R<sup>2</sup>, -C(O)-N(R<sup>2</sup>)<sub>2</sub>, halo or -CF<sub>3</sub>;
- 10 each R<sup>2</sup> is independently selected from the group consisting of H and C<sub>1</sub>-C<sub>3</sub> alkyl optionally substituted with Q;
- each x is independently 0 or 1;
- each R<sup>3</sup> is independently selected from the group
- 15 consisting of H, Ht, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>2</sub>-C<sub>6</sub> alkenyl wherein any member of said R<sup>3</sup>, except H, may be optionally substituted with one or more substituents selected from the group consisting of -OR<sup>2</sup>, -C(O)-NH-R<sup>2</sup>, -S(O)<sub>n</sub>-N(R<sup>2</sup>)(R<sup>2</sup>), Ht, -CN, -SR<sup>2</sup>, -CO<sub>2</sub>R<sup>2</sup>, NR<sup>2</sup>-C(O)-R<sup>2</sup>;
- 20 each n is independently 1 or 2;
- G, when present, is selected from H, R<sup>7</sup> or C<sub>1</sub>-C<sub>4</sub> alkyl, or, when G is C<sub>1</sub>-C<sub>4</sub> alkyl, G and R<sup>7</sup> are bound to one another either directly or through a C<sub>1</sub>-C<sub>3</sub> linker to form a heterocyclic ring; or
- 25 when G is not present (i.e., when x in (G)<sub>x</sub> is 0), then the nitrogen to which G is attached is bound directly to the R<sup>7</sup> group on -OR<sup>7</sup>;
- each D and D' is independently selected from the group consisting of Q; C<sub>1</sub>-C<sub>5</sub> alkyl, which may be
- 30 optionally substituted with one or more groups selected from C<sub>3</sub>-C<sub>6</sub> cycloalkyl, -OR<sup>2</sup>, -R<sup>3</sup>, -O-Q, -S-Q and Q; C<sub>2</sub>-C<sub>4</sub> alkenyl, which may be optionally substituted with one or more groups selected from the group consisting of C<sub>3</sub>-C<sub>6</sub> cycloalkyl, -OR<sup>2</sup>, R<sup>3</sup>, O-Q and Q; C<sub>3</sub>-C<sub>6</sub> cycloalkyl, which
- 35 may be optionally substituted with or fused with Q; and

C<sub>5</sub>-C<sub>6</sub> cycloalkenyl, which may be optionally substituted with or fused with R<sup>6</sup>;


each E is independently selected from the group consisting of Ht; -O-Ht; Ht-Ht; -O-R<sup>3</sup>; -NR<sup>2</sup>R<sup>3</sup>; C<sub>1</sub>-C<sub>6</sub> alkyl, which may be optionally substituted with one or more groups selected from the group consisting of R<sup>4</sup> and Ht; and C<sub>2</sub>-C<sub>6</sub> alkenyl, which may be optionally substituted with one or more groups selected from the group consisting of R<sup>4</sup> and Ht; C<sub>3</sub>-C<sub>6</sub> saturated carbocycle, which is optionally substituted with one or more groups selected from R<sup>4</sup> or Ht; or C<sub>5</sub>-C<sub>6</sub> unsaturated carbocycle, which is optionally substituted with one or more groups selected from R<sup>4</sup> or Ht;

each R<sup>4</sup> is independently selected from the group consisting of OR<sup>2</sup>, -C(O)-NHR<sup>2</sup>, S(O)<sub>2</sub>-NHR<sup>2</sup>, halo, NR<sup>2</sup>-C(O)-R<sup>2</sup> and -CN;

each R<sup>5</sup> is independently selected from the group consisting of H and C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with aryl; and

each R<sup>6</sup> is independently selected from the group consisting of aryl, carbocycle and heterocycle, wherein said aryl, carbocycle or heterocycle may be optionally substituted with one or more groups selected from the group consisting of oxo, -OR<sup>5</sup>, -R<sup>5</sup>, N(R<sup>5</sup>)(R<sup>5</sup>), N(R<sup>5</sup>)-C(O)-R<sup>5</sup>, -R<sup>5</sup>-OH, -CN, CO<sub>2</sub>R<sup>5</sup>, C(O)-N(R<sup>5</sup>)(R<sup>5</sup>), halo and CF<sub>3</sub>;

each R<sup>7</sup> is independently selected from



wherein each M is independently selected from H, Li, Na, K, Mg, Ca, Ba, -N(R<sup>2</sup>)<sub>4</sub>, C<sub>1</sub>-C<sub>12</sub>-alkyl, C<sub>2</sub>-C<sub>12</sub>-alkenyl, -R<sup>6</sup>; wherein 1 to 4 -CH<sub>2</sub> radicals of the alkyl or alkenyl group, other than the -CH<sub>2</sub> that is bound to Z, is optionally replaced by a heteroatom group selected



from O, S, S(O), S(O<sub>2</sub>), or N(R<sup>2</sup>); and wherein any hydrogen in said alkyl, alkenyl or R<sup>6</sup> is optionally replaced with a substituent selected from oxo, -OR<sup>2</sup>, -R<sup>2</sup>, N(R<sup>2</sup>)<sub>2</sub>, N(R<sup>2</sup>)<sub>3</sub>, R<sup>2</sup>OH, -CN, -CO<sub>2</sub>R<sup>2</sup>, -C(O)-N(R<sup>2</sup>)<sub>2</sub>, S(O)<sub>2</sub>-N(R<sup>2</sup>)<sub>2</sub>, N(R<sup>2</sup>)-C(O)-R<sub>2</sub>,  
5 C(O)R<sup>2</sup>, -S(O)<sub>n</sub>-R<sup>2</sup>, OCF<sub>3</sub>, -S(O)<sub>n</sub>-R<sup>6</sup>, N(R<sup>2</sup>)-S(O)<sub>2</sub>(R<sup>2</sup>), halo, -CF<sub>3</sub>, or -NO<sub>2</sub>;

M' is H, C<sub>1</sub>-C<sub>12</sub>-alkyl, C<sub>2</sub>-C<sub>12</sub>-alkenyl, -R<sup>6</sup>;  
wherein 1 to 4 -CH<sub>2</sub> radicals of the alkyl or alkenyl group is optionally replaced by a heteroatom group selected  
10 from O, S, S(O), S(O<sub>2</sub>), or N(R<sup>2</sup>); and wherein any hydrogen in said alkyl, alkenyl or R<sup>6</sup> is optionally replaced with a substituent selected from oxo, -OR<sup>2</sup>, -R<sup>2</sup>, -N(R<sup>2</sup>)<sub>2</sub>, N(R<sup>2</sup>)<sub>3</sub>, -R<sup>2</sup>OH, -CN, -CO<sub>2</sub>R<sup>2</sup>, -C(O)-N(R<sup>2</sup>)<sub>2</sub>, -S(O)<sub>2</sub>-N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)-C(O)-R<sub>2</sub>, -C(O)R<sup>2</sup>, -S(O)<sub>n</sub>-R<sup>2</sup>, -OCF<sub>3</sub>, -S(O)<sub>n</sub>-R<sup>6</sup>, -N(R<sup>2</sup>)-S(O)<sub>2</sub>(R<sup>2</sup>),  
15 halo, -CF<sub>3</sub>, or -NO<sub>2</sub>;

Z is O, S, N(R<sup>2</sup>)<sub>2</sub>, or, when M is absent, H;

Y is P or S;

X is O or S; and

R<sup>9</sup> is C(R<sup>2</sup>)<sub>2</sub>, O or N(R<sup>2</sup>); and wherein when Y is  
20 S, Z is not S; and

R<sup>6</sup> is a 5-6 membered saturated, partially saturated or unsaturated carbocyclic or heterocyclic ring system, or an 8-10 membered saturated, partially saturated or unsaturated bicyclic ring system; wherein  
25 any of said heterocyclic ring systems contains one or more heteroatoms selected from O, N, S, S(O)<sub>n</sub> or N(R<sup>2</sup>); and wherein any of said ring systems optionally contains 1 to 4 substituents independently selected from OH, C<sub>1</sub>-C<sub>4</sub> alkyl, O-C<sub>1</sub>-C<sub>4</sub> alkyl or OC(O)C<sub>1</sub>-C<sub>4</sub> alkyl.

30 It is also an object of this invention to provide pharmaceutical compositions comprising the sulfonamides of formula I and methods for their use as inhibitors of HIV aspartyl protease.

DETAILED DESCRIPTION OF THE INVENTION

In order that the invention herein described may be more fully understood, the following detailed description is set forth. In the description, the following abbreviations are used:

	<u>Designation</u>	<u>Reagent or Fragment</u>
	Ac	acetyl
	Me	methyl
10	Et	ethyl
	Bn	benzyl
	Trityl	triphenylmethyl
	Asn	D- or L-asparagine
	Ile	D- or L-isoleucine
15	Phe	D- or L-phenylalanine
	Val	D- or L-valine
	Boc	tert-butoxycarbonyl
	Cbz	benzyloxycarbonyl (carbobenzyloxy)
	Fmoc	9-fluorenylmethoxycarbonyl
20	DCC	dicyclohexylcarbodiimide
	DIC	diisopropylcarbodiimide
	EDC	1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
	HOBt	1-hydroxybenzotriazole
25	HOSu	1-hydroxysuccinimide
	TFA	trifluoroacetic acid
	DIEA	diisopropylethylamine
	DBU	1,8-diazabicyclo(5.4.0)undec-7-ene
	EtOAc	ethyl acetate
30	t-Bu	tert-butyl
	iBu	iso-butyl
	DMF	dimethylformamide
	THP	tertrahydropyran
	THF	tetrahydrofuran
35	TMSCl	chlorotrimethylsilane

DMSO

dimethylsulfoxide

The following terms are employed herein:

Unless expressly stated to the contrary, the  
5 terms "SO<sub>2</sub>-" and "S(O)<sub>2</sub>-" as used herein refer to a  
sulfone or sulfone derivative (i.e., both appended groups  
linked to the S), and not a sulfinic ester.

The term "backbone" refers to the structural  
representation of a compound of this invention, as set  
10 forth in the figures drawn in this application.

For the compounds of formula I, and  
intermediates thereof, the stereochemistry of the -OR<sup>7</sup>  
group is defined relative to D on the adjacent carbon  
atom, when the molecule is drawn in an extended zig-zag  
15 representation (such as that drawn for compounds of  
formula X, XI, XII, XIII, XX, XXI, and XXII). If both -  
OR<sup>7</sup> and D reside on the same side of the plane defined by  
the extended backbone of the compound, the  
stereochemistry of the -OR<sup>7</sup> bearing carbon atom will be  
20 referred to as "syn". If -OR<sup>7</sup> and D reside on opposite  
sides of that plane, the stereochemistry of the -OR<sup>7</sup>  
bearing carbon atom will be referred to as "anti".

As used herein, the term "alkyl", alone or in  
combination with any other term, refers to a straight-  
25 chain or branch-chain saturated aliphatic hydrocarbon  
radical containing the specified number of carbon atoms,  
or where no number is specified, preferably from 1-10 and  
more preferably from 1-5 carbon atoms. Examples of alkyl  
radicals include, but are not limited to, methyl, ethyl,  
30 n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-  
butyl, pentyl, isoamyl, n-hexyl and the like.

The term "alkenyl", alone or in combination  
with any other term, refers to a straight-chain or  
branched-chain mono- or poly-unsaturated aliphatic  
35 hydrocarbon radical containing the specified number of

carbon atoms, or where no number is specified, preferably from 2-10 carbon atoms and more preferably, from 2-6 carbon atoms. Examples of alkenyl radicals include, but are not limited to, ethenyl, E- and Z-propenyl, isopropenyl, E- and Z-butenyl, E- and Z-isobutenyl, E- and Z-pentenyl, E- and Z-hexenyl, E,E-, E,Z-, Z,E- and Z,Z-hexadienyl and the like.

The term "aryl", alone or in combination with any other term, refers to a carbocyclic aromatic radical (such as phenyl or naphthyl) containing the specified number of carbon atoms, preferably from 6-14 carbon atoms, and more preferably from 6-10 carbon atoms. Examples of aryl radicals include, but are not limited to phenyl, naphthyl, indenyl, indanyl, azulenyl, fluorenyl, anthracenyl and the like.

The term "cycloalkyl", alone or in combination with any other term, refers to a cyclic saturated hydrocarbon radical containing the specified number of carbon atoms, preferably from 3-7 carbon atoms. Examples of cycloalkyl radicals include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.

The term "cycloalkenyl", alone or in combination with any other term, refers to a cyclic hydrocarbon radical containing the specified number of carbon atoms with at least one endocyclic carbon-carbon bond. Where no number of carbon atoms is specified, a cycloalkenyl radical preferably has from 5-7 carbon atoms. Examples of cycloalkenyl radicals include, but are not limited to, cyclopentenyl, cyclohexenyl, cyclopentadienyl and the like.

The term "THF" refers to a tetrahydrofuran ring attached at any ring carbon resulting in a stable structure.

The term "carbocycle" refers to a stable nonaromatic 3 to 8-membered carbon ring which may be saturated, mono-unsaturated or poly-unsaturated. The carbocycle may be attached at any endocyclic carbon atom which results in a stable structure. Preferred carbocycles have 5-6 carbons.

The term "heterocycle", unless otherwise defined herein, refers to a stable 3-7 membered monocyclic heterocyclic ring or 8-11 membered bicyclic heterocyclic ring which is either saturated or unsaturated, and which may be optionally benzofused if monocyclic. Each heterocycle consists of one or more carbon atoms and from one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. As used herein, the terms "nitrogen and sulfur heteroatoms" include any oxidized form of nitrogen and sulfur, and the quaternized form of any basic nitrogen. In addition, any ring nitrogen may be optionally substituted with a substituent  $R^2$ , as defined herein for compounds of formula I. A heterocycle may be attached at any endocyclic carbon or heteroatom which results in the creation of a stable structure. A heterocycle may be attached at any endocyclic carbon or heteroatom which results in the creation of a stable structure. Preferred heterocycles include 5-7 membered monocyclic heterocycles and 8-10 membered bicyclic heterocycles. Preferred heterocycles defined above include, for example, benzimidazolyl, imidazolyl, imidazolinoyl, imidazolidinyl, quinolyl, isoquinolyl, indolyl, indazolyl, indazolinolyl, perhydropyridazyl, pyridazyl, pyridyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazinyl, quinoxolyl, piperidinyl, pyranyl, pyrazolinyl, piperazinyl, pyrimidinyl, pyridazinyl, morpholinyl, thiamorpholinyl, furyl, thienyl, triazolyl, thiazolyl,  $\beta$ -carbolinyl, tetrazolyl, thiazolidinyl, benzofuranoyl,

thiamorpholinyl sulfone, oxazolyl, benzoxazolyl, oxopiperidinyl, oxopyrroldinyl, oxoazepinyl, azepinyl, isoxazolyl, isothiazolyl, furazanyl, tetrahydropyranyl, tetrahydrofuranyl, thiazolyl, thiadiazoyl, dioxolyl, 5 dioxinyl, oxathieryl, benzodioxolyl, dithieryl, thiophenyl, tetrahydrothiophenyl and sulfolanyl.

The term "halo" refers to a radical of fluorine, chlorine, bromine or iodine.

The term "linker" refers to a structural unit 10 through which two other moieties are joined. For example, the term "C<sub>1</sub>-C<sub>3</sub> alkyl linker" refers to a 1-3 carbon unit which attaches two other moieties together.

The terms "oxygenated heterocycle" and "heterocycle containing endocyclic oxygen atoms" are used 15 interchangeably and refer to a monocyclic or bicyclic heterocycle containing a specified number of endocyclic oxygen atoms. Preferably, such oxygenated heterocycles contain only endocyclic oxygen heteroatoms. Examples of oxygenated heterocycles, include, but are not limited to: 20 dioxanyl, dioxolanyl, tetrahydrofuranyl, tetrahydrofurodihydrofuranyl, tetrahydropyranyl, tetrahydropyranodihydrofuranyl, dihydropyranyl, tetrahydrofurofuranyl and tetrahydropyranofuranyl.

The terms "HIV protease" and "HIV aspartyl 25 protease" are used interchangeably and refer to the aspartyl protease encoded by the human immunodeficiency virus type 1 or 2. In a preferred embodiment of this invention, these terms refer to the human immunodeficiency virus type 1 aspartyl protease.

30 The term "antiviral agent" or "anti-retroviral agent" refers to a compound or drug which possesses viral inhibitory activity. Such agents include reverse transcriptase inhibitors (including nucleoside and non-nucleoside analogs) and protease inhibitors. Preferably 35 the protease inhibitor is an HIV protease inhibitor.

Examples of nucleoside analog reverse transcriptase inhibitors include, but are not limited to, zidovudine (AZT), dideoxycytidine (ddC), didanosine (ddI), stavudine (d4T), 3TC, 935U83, 1592U89 and 524W91. Examples of non-  
5 nucleoside analog reverse transcriptase inhibitors include, but are not limited to delavirdine (U90) and nevirapine. Examples of HIV protease inhibitors include, but are not limited to, saquinavir (Ro 318959), L-735,524, ABT 538 (A80538), AG 1343, XM 412, XM 450, BMS  
10 186318 and CPG 53,437,

The term "pharmaceutically effective amount" refers to an amount effective in treating HIV infection in a patient either as monotherapy or in combination with other agents. The term "treating" as used herein refers  
15 to the alleviation of symptoms of a particular disorder in a patient or the improvement of an ascertainable measurement associated with a particular disorder. Specifically, with respect to HIV, effective treatment using the compounds and compositions of this invention  
20 would result in an improvement in an HIV associated ascertainable measurement. Such measurements include, but are not limited to, reduction in viral load in plasma or another defined tissue compartment as measured by, e.g. RT-PCR or branched-chain DNA PCR or culturable virus  
25 measurements,  $\alpha$ -2 microglobulin or p24 levels, number of CD<sub>4</sub><sup>+</sup> cells or ratio of CD<sub>4</sub><sup>+</sup>/CD<sub>8</sub><sup>+</sup> cells, or functional markers such as improvement in quality of life or ability to carry out normal functions or reduction in immunosuppression-related effects. The term  
30 "prophylactically effective amount" refers to an amount effective in preventing HIV infection in a patient. As used herein, the term "patient" refers to a mammal, including a human.

The term "pharmaceutically acceptable carrier  
35 or adjuvant" refers to a carrier or adjuvant that may be

administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the antiretroviral agent.

The term "point of attachment" refers to the atom through which a moiety is attached to a specified structure. When a point of attachment may be optionally methylated, the point of attachment is the carbon atom through which a moiety is attached to a specified structure.

The term "substituted", whether express or implied and whether preceded by the term "optionally" or not, refers to the replacement of one or more hydrogen radicals in a given structure with the radical of a specified substituent. When more than one position in a given structure may be substituted with a substituent selected from a specified group, the substituents may be either the same or different at every position. Typically, when a structure may be optionally substituted, 0-3 substitutions are preferred, and 0-1 substitution is most preferred. Most preferred substituents are those which enhance protease inhibitory activity or intracellular antiviral activity in permissive mammalian cells or immortalized mammalian cell lines, or which enhance deliverability by enhancing solubility characteristics or enhancing pharmacokinetic or pharmacodynamic profiles as compared to the unsubstituted compound. Other most preferred substituents include those used in the compounds shown in Table I.

Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acids include



hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic, p-toluenesulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic and benzenesulfonic acids. Preferred acids include hydrochloric, sulfuric, methanesulfonic and ethanesulfonic acids. Methanesulfonic acid is most preferred. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.

Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(C<sub>1-4</sub> alkyl)<sub>4</sub><sup>+</sup> salts.

The term "thiocarbamates" refers to compounds containing the functional group N-SO<sub>2</sub>-O.

The compounds of this invention contain one or more asymmetric carbon atoms and thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly included in the present invention. Each stereogenic carbon may be of the R or S configuration. The explicitly shown hydroxyl is also preferred to be syn to D, in the extended zig-zag conformation between the nitrogens shown in compounds of formula I.


Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds. The term "stable", as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed

herein (e.g., therapeutic or prophylactic administration to a mammal or for use in affinity chromatography applications). Typically, such compounds are stable at a temperature of 40°C or less, in the absence of moisture or  
5 other chemically reactive conditions, for at least a week.

The compounds of the present invention may be used in the form of salts derived from inorganic or organic acids. Included among such acid salts, for  
10 example, are the following: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate,  
15 glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-  
20 phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate and undecanoate.

This invention also envisions the quaternization of any basic nitrogen-containing groups of  
25 the compounds disclosed herein. The basic nitrogen can be quaternized with any agents known to those of ordinary skill in the art including, for example, lower alkyl halides, such as methyl, ethyl, propyl and butyl chlorides, bromides and iodides; dialkyl sulfates  
30 including dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myrist\_ and stearyl chlorides, bromides and iodides; and aralkyl halides including benzyl and phenethyl bromides. Water or oil-soluble or dispersible products may be obtained by  
35 such quaternization.

The novel sulfonamides of this invention are those of formula I:



5

wherein:

each  $R^1$  is independently selected from the group consisting of  $C(O)-$ ,  $-S(O)_2-$ ,  $-C(O)-C(O)-$ ,  $-O-C(O)-$ ,  $-O-S(O)_2-$ ,  $-NR^2-S(O)_2-$ ,  $-NR^2-C(O)-$  and  $-NR^2-C(O)-C(O)-$ ;

each A is independently selected from the group consisting of 5-7 membered monocyclic heterocycles containing from 1-3 endocyclic heteroatoms, which may be optionally methylated at the point of attachment, optionally benzofused, optionally attached through a  $C_1-C_3$  alkyl linker and optionally fused with a 5-7 membered monocyclic heterocycle containing from 1-2 endocyclic heteroatoms, and wherein unmethylated THF is expressly excluded;

each Ht is independently selected from  $C_3-C_7$  cycloalkyl;  $C_5-C_7$  cycloalkenyl;  $C_6-C_{10}$  aryl; or a 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N,  $N(R^2)$ , O, S and  $S(O)_n$ ; wherein said aryl or said heterocycle is optionally fused to Q; and wherein any member of said Ht is optionally substituted with one or more substituents independently selected from oxo,  $-OR^2$ ,  $SR^2$ ,  $-R^2$ , -

$N(R^2)(R^2)$ ,  $-R^2-OH$ ,  $-CN$ ,  $-CO_2R^2$ ,  $-C(O)-N(R^2)_2$ ,  $-S(O)_2-N(R^2)_2$ ,  
 $-N(R^2)-C(O)-R^2$ ,  $-C(O)-R^2$ ,  $-S(O)_n-R^2$ ,  $-OCF_3$ ,  $-S(O)_n-Q$ ,  
 methylenedioxy,  $-N(R^2)-S(O)_2(R^2)$ , halo,  $-CF_3$ ,  $-NO_2$ ,  $Q$ ,  $-OQ$ ,  
 $-OR^7$ ,  $-SR^7$ ,  $-R^7$ ,  $-N(R^2)(R^7)$  or  $-N(R^7)_2$ ;

5 each  $Q$  is independently selected from a 3-7  
 membered saturated, partially saturated or unsaturated  
 carbocyclic ring system; or a 5-7 membered saturated,  
 partially saturated or unsaturated heterocyclic ring  
 containing one or more heteroatoms selected from O, N, S,  
 10  $S(O)_n$  or  $N(R^2)$ ; wherein  $Q$  is optionally substituted with  
 one or more groups selected from oxo,  $-OR^2$ ,  $-R^2$ ,  $-N(R^2)_2$ ,  
 $-N(R^2)-C(O)-R^2$ ,  $-R^2-OH$ ,  $-CN$ ,  $-CO_2R^2$ ,  $-C(O)-N(R^2)_2$ , halo or  
 $-CF_3$ ;

each  $R^2$  is independently selected from the group  
 15 consisting of H and  $C_1-C_3$  alkyl optionally substituted  
 with  $Q$ ;

each  $x$  is independently 0 or 1;

each  $R^3$  is independently selected from the group  
 consisting of H, Ht,  $C_1-C_6$  alkyl and  $C_2-C_6$  alkenyl wherein  
 20 any member of said  $R^3$ , except H, may be optionally  
 substituted with one or more substituents selected from  
 the group consisting of  $-OR^2$ ,  $-C(O)-NH-R^2$ ,  $-S(O)_n-$   
 $N(R^2)(R^2)$ , Ht,  $-CN$ ,  $-SR^2$ ,  $-CO_2R^2$ ,  $NR^2-C(O)-R^2$ ;

each  $n$  is independently 1 or 2;

25  $G$ , when present, is selected from H,  $R^7$  or  $C_1-C_4$   
 alkyl, or, when  $G$  is  $C_1-C_4$  alkyl,  $G$  and  $R^7$  are bound to one  
 another either directly or through a  $C_1-C_3$  linker to form  
 a heterocyclic ring; or

when  $G$  is not present (i.e., when  $x$  in  $(G)_x$  is  
 30 0), then the nitrogen to which  $G$  is attached is bound  
 directly to the  $R^7$  group on  $-OR^7$ ;

each  $D$  and  $D'$  is independently selected from  
 the group consisting of  $Q$ ;  $C_1-C_3$  alkyl, which may be  
 optionally substituted with one or more groups selected  
 35 from  $C_3-C_6$  cycloalkyl,  $-OR^2$ ,  $-R^3$ ,  $-O-Q$ ,  $-S-Q$  and  $Q$ ;  $C_2-C_4$

alkenyl, which may be optionally substituted with one or more groups selected from the group consisting of C<sub>3</sub>-C<sub>6</sub> cycloalkyl, -OR<sup>2</sup>, R<sup>3</sup>, O-Q and Q; C<sub>3</sub>-C<sub>6</sub> cycloalkyl, which may be optionally substituted with or fused with Q; and  
 5 C<sub>5</sub>-C<sub>6</sub> cycloalkenyl, which may be optionally substituted with or fused with R<sup>6</sup>;


each E is independently selected from the group consisting of Ht; -O-Ht; Ht-Ht; -O-R<sup>3</sup>; -NR<sup>2</sup>R<sup>3</sup>; C<sub>1</sub>-C<sub>6</sub> alkyl, which may be optionally substituted with one or more  
 10 groups selected from the group consisting of R<sup>4</sup> and Ht; and C<sub>2</sub>-C<sub>6</sub> alkenyl, which may be optionally substituted with one or more groups selected from the group consisting of R<sup>4</sup> and Ht; C<sub>3</sub>-C<sub>6</sub> saturated carbocycle, which is optionally substituted with one or more groups  
 15 selected from R<sup>4</sup> or Ht; or C<sub>5</sub>-C<sub>6</sub> unsaturated carbocycle, which is optionally substituted with one or more groups selected from R<sup>4</sup> or Ht;

each R<sup>4</sup> is independently selected from the group consisting of OR<sup>2</sup>, -C(O)-NHR<sup>2</sup>, S(O)<sub>2</sub>-NHR<sup>2</sup>, halo, NR<sup>2</sup>-C(O)-  
 20 R<sup>2</sup> and -CN;

each R<sup>5</sup> is independently selected from the group consisting of H and C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with aryl; and

each R<sup>6</sup> is independently selected from the group  
 25 consisting of aryl, carbocycle and heterocycle, wherein said aryl, carbocycle or heterocycle may be optionally substituted with one or more groups selected from the group consisting of oxo, -OR<sup>5</sup>, -R<sup>5</sup>, N(R<sup>5</sup>)(R<sup>5</sup>), N(R<sup>5</sup>)-C(O)-R<sup>5</sup>, -R<sup>5</sup>-OH, -CN, CO<sub>2</sub>R<sup>5</sup>, C(O)-N(R<sup>5</sup>)(R<sup>5</sup>), halo and CF<sub>3</sub>;

30 each R<sup>7</sup> is independently selected from



35 wherein each M is independently selected

from H, Li, Na, K, Mg, Ca, Ba,  $-N(R^2)_4$ ,  $C_1$ - $C_{12}$ -alkyl,  $C_2$ - $C_{12}$ -alkenyl,  $-R^6$ ; wherein 1 to 4  $-CH_2$  radicals of the alkyl or alkenyl group, other than the  $-CH_2$  that is bound to Z, is optionally replaced by a heteroatom group selected  
 5 from O, S,  $S(O)$ ,  $S(O)_2$ , or  $N(R^2)$ ; and wherein any hydrogen in said alkyl, alkenyl or  $R^6$  is optionally replaced with a substituent selected from oxo,  $-OR^2$ ,  $-R^2$ ,  $N(R^2)_2$ ,  $N(R^2)_3$ ,  $R^2OH$ ,  $-CN$ ,  $-CO_2R^2$ ,  $-C(O)-N(R^2)_2$ ,  $S(O)_2-N(R^2)_2$ ,  $N(R^2)-C(O)-R_2$ ,  $C(O)R^2$ ,  $-S(O)_n-R^2$ ,  $OCF_3$ ,  $-S(O)_n-R^6$ ,  $N(R^2)-S(O)_2(R^2)$ , halo,  $-$   
 10  $CF_3$ , or  $-NO_2$ ;

$M'$  is H,  $C_1$ - $C_{12}$ -alkyl,  $C_2$ - $C_{12}$ -alkenyl,  $-R^6$ ; wherein 1 to 4  $-CH_2$  radicals of the alkyl or alkenyl group is optionally replaced by a heteroatom group selected from O, S,  $S(O)$ ,  $S(O)_2$ , or  $N(R^2)$ ; and wherein any hydrogen  
 15 in said alkyl, alkenyl or  $R^6$  is optionally replaced with a substituent selected from oxo,  $-OR^2$ ,  $-R^2$ ,  $-N(R^2)_2$ ,  $N(R^2)_3$ ,  $-R^2OH$ ,  $-CN$ ,  $-CO_2R^2$ ,  $-C(O)-N(R^2)_2$ ,  $-S(O)_2-N(R^2)_2$ ,  $-N(R^2)-C(O)-R_2$ ,  $-C(O)R^2$ ,  $-S(O)_n-R^2$ ,  $-OCF_3$ ,  $-S(O)_n-R^6$ ,  $-N(R^2)-S(O)_2(R^2)$ , halo,  $-CF_3$ , or  $-NO_2$ ;

20  $Z$  is O, S,  $N(R^2)_2$ , or, when M is absent, H;

$Y$  is P or S;

$X$  is O or S; and

$R^9$  is  $C(R^2)_2$ , O or  $N(R^2)$ ; and wherein when Y is S, Z is not S; and

25  $R^6$  is a 5-6 membered saturated, partially saturated or unsaturated carbocyclic or heterocyclic ring system, or an 8-10 membered saturated, partially saturated or unsaturated bicyclic ring system; wherein any of said heterocyclic ring systems contains one or  
 30 more heteroatoms selected from O, N, S,  $S(O)_n$  or  $N(R^2)$ ; and wherein any of said ring systems optionally contains 1 to 4 substituents independently selected from OH,  $C_1$ - $C_4$  alkyl, O- $C_1$ - $C_4$  alkyl or  $OC(O)C_1$ - $C_4$  alkyl.

Preferred compounds of formula I have the following definitions for one or more of the below-specified substituents;

each  $R^1$  is  $-O-C-(O)-$ ;

5 each A is independently selected from the group consisting of 5-6 membered monocyclic heterocycles containing from 1-2 endocyclic oxygen atoms, which may be optionally methylated at the point of attachment, optionally attached through a  $C_1-C_3$  alkyl linker and  
10 optionally fused with a 5-6 membered monocyclic heterocycle containing from 1-2 endocyclic oxygen atoms, and more preferably, A is selected from the group consisting of dioxanyl (preferably, 1,3- dioxanyl), dioxolanyl, dioxolanylmethyl, 3-methyl THF,  
15 tetrahydrofurofuranyl, tetrahydrofurodihydrofuranyl, tetrahydropyranofuranyl, tetrahydropyranodihydrofuranyl, pyranyl, dihydropyranyl and tetrahydropyranyl. Most preferably, A is 1,3-dioxanyl attached at the 5-position.

each D is  $C_1-C_5$  alkyl, which may be optionally substituted with one or more Ht, more preferably D is  $C_1-C_3$  alkyl, which may be optionally substituted with one  
20 group selected from  $C_6-C_{10}$  aryl and  $C_3-C_6$  cycloalkyl, even more preferably D is selected from benzyl, isobutyl, cyclopentylmethyl, and cyclohexylmethyl and most  
25 preferably, D is benzyl or isobutyl;



each D' is selected from the group consisting of  $C_1-C_6$  alkyl optionally substituted with  $R^6$  (wherein each  $R^6$  is independently selected from the group consisting of carbocycle and heterocycle, wherein said  
30 heterocycle or carbocycle may be optionally substituted with one or more groups selected from the group consisting of oxo,  $OR^5$ ,  $-R^5$ ,  $N(R^5)(R^5)$ ,  $N(R^5)-C(O)-R^5$ ,  $-R^5-OH$ ,  $-CN$ ,  $CO_2R^5$ ,  $C(O)-N(R^5)(R^5)$ , halo and  $CF_3$  and each  $R^5$  is independently selected from the group consisting of H and  
35  $C_1-C_3$  alkyl), and more preferably D' is selected from the





*This Page Blank (uspto)*







group consisting of  $C_1C_4$  alkyl optionally substituted with one 3-6 membered carbocycle or one 5-6 membered heterocycle, and most preferably,  $D'$  is selected from the group consisting of isobutyl, cyclopentylmethyl and cyclohexylmethyl;

- 5 each  $E$  is  $Ht$  and more preferably,  $E$  is phenyl substituted with 0-2 substituents chosen from the group consisting of  $OH$ ,  $OR^7$ ,  $OCH_3$ ,  $NH_2$ ,  $NHCOCH_3$ ,  $SCH_3$ , and  $CH_3$ ; or phenyl fused with 5-6 membered heterocycle, and even
- 10 more preferably,  $E$  is phenyl substituted with one substituent selected from the group consisting of  $OH$ ,  $OR^7$ ,  $OCH_3$ ,  $NH_2$ ,  $NHCOCH_3$ ,  $SCH_3$ , and  $CH_3$ ; or phenyl fused with 5-6 membered heterocycle, and most preferably,  $E$  is phenyl substituted with  $NH_2$ ,  $NHR^7$  or  $N(R^7)_2$  (preferably in the
- 15 meta- or para-position).


Preferably  $R^7$  is , ,



23



10



$\text{PO}_3\text{K}_2$ ,  $\text{PO}_3\text{Ca}$ ,  $\text{PO}_3$ -spermine,  $\text{PO}_3$ -(spermidine)<sub>2</sub> or  $\text{PO}_3$ -(meglamine)<sub>2</sub>.

15

It will be understood by those of skill in the art that component M or M' in the formulae set forth herein will have either a covalent, a covalent/zwitterionic, or an ionic association with either Z or R<sup>9</sup> depending upon the actual choice for M or M'. When M or

20 M' is hydrogen, alkyl, alkenyl, or R<sup>6</sup>, M or M' is covalently bound to R<sup>9</sup> or Z. If M is a mono- or bivalent metal or other charged species (i.e.,  $\text{NH}_4^+$ ), there is an ionic interaction between M and Z and the resulting compound is a salt.

25


When x is 0 in (M)<sub>x</sub>, Z may be a charged species. When that occurs, the other M may be oppositely charged

to produce a 0 net charge on the molecule.  
Alternatively, the counter ion may be located elsewhere in the molecule.

Except where expressly provided to the contrary, as used herein, the definitions of variables A, R<sup>1</sup>-R<sup>4</sup>, R<sup>6</sup>-R<sup>9</sup>, Ht, B, x, n, D, D', M, Q, X, Y, Z and E are to be taken as they are defined above for the compounds of formula I.

























Table I illustrates preferred compounds of this invention:





























TABLE 1




15

COMPOUND	A	D	D'	E
1				
2				
3				

4				
5				
6				
7 (Isomer A)	 ( + ) or ( - )			
8 (Isomer B)	 ( + ) or ( - )			
9 (Isomer A)	 ( + ) or ( - )			

10 (Isomer B)	 ( + ) or ( - )			
11	 ( + )			
12	 ( + )			
13				
14				
15				
16				


The prodrugs of the present invention may be synthesized using conventional synthetic techniques. WO 96/33187 discloses the synthesis of compounds of formula:



wherein A, R<sup>1</sup>, D, D' and E are as defined above.


Prodrugs of formula (I) of the present invention can be readily synthesized from the '187 compounds using conventional techniques. One of skill in the art would be well aware of conventional synthetic reagents to convert the -OH group of the '187 compounds to a desired -OR<sup>7</sup> functionality of the present invention, wherein R<sup>7</sup> is as defined above. The relative ease with which the compounds of this invention can be synthesized represents an enormous advantage in the large scale production of these compounds.

For example, VX-478, a compound disclosed in United States patent 5,585,397, can be readily converted to the corresponding bis-phosphate ester derivative, as shown below:



Alternatively, if the monophosphate ester of VX-478 is desired, then the synthetic scheme can be readily adapted by beginning with the 4-nitrophenyl derivative of VX-478, as shown below:


28



Although unmethylated tetrahydrofuran  
embodiments of formula I, such as VX 478, are expressly  
5 excluded from the present invention, one of skill in the  
art would readily be able to prepare the corresponding  
monophosphate and bis-phosphate esters of the present  
invention using similar reaction conditions.

Further examples of specific compounds which  
10 may be converted to the prodrugs of this invention by  
similar techniques (and the syntheses of those  
intermediates to the compounds of the present invention)  
are disclosed in WO 94/05639 and '397 patent, the  
disclosures of which are herein incorporated by  
15 reference.

Pharmaceutically acceptable salts of the  
compounds of the present invention may be readily  
prepared using known techniques. For example, the  
disodium salt of the mono-phosphate ester shown above can  
20 be prepared as shown below:




The compounds of this invention may be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.

Without being bound by theory, we believe that two different mechanisms are involved in converting the prodrugs of this invention into the active drug, depending upon the structure of the prodrug. The first mechanism involves the enzymatic or chemical transformation of the prodrug species into the active form. The second mechanism involves the enzymatic or chemical cleavage of a functionality on the prodrug to produce the active compound.


The chemical or enzymatic transformation can involve to transfer of a functional group (i.e.,  $\text{R}^1$ ) from one heteroatom within the molecule to another heteroatom. This transfer is demonstrated in the chemical reactions shown below:



30



and



5

The cleavage mechanism is demonstrated by the reaction below where a phosphate ester-containing prodrug is converted into the active form of the drug by removal of the phosphate group.



These protease inhibitors and their utility as inhibitors of aspartyl proteases are described in WO 96/33187, the disclosure of which is incorporated herein by reference.

The prodrugs of the present invention are characterized by unexpectedly high aqueous solubility. This solubility facilitates administration of higher doses of the prodrug, resulting in a greater drug load per unit dosage. The prodrugs of the present invention are also characterized by facile hydrolytic cleavage to

release the active aspartyl protease inhibitor in vivo.  
The high aqueous solubility and the facile in vivo  
metabolism result in a greater bioavailability of the  
drug. As a result, the pill burden on a patient is  
5 significantly reduced.

The prodrugs of this invention may be employed  
in a conventional manner for the treatment of viruses,  
such as HIV and HTLV, which depend on aspartyl proteases  
for obligatory events in their life cycle. Such methods  
10 of treatment, their dosage levels and requirements may be  
selected by those of ordinary skill in the art from  
available methods and techniques. For example, a prodrug  
of this invention may be combined with a pharmaceutically  
acceptable adjuvant for administration to a virally-  
15 infected patient in a pharmaceutically acceptable manner  
and in an amount effective to lessen the severity of the  
viral infection.

Alternatively, the prodrugs of this invention  
may be used in vaccines and methods for protecting  
20 individuals against viral infection over an extended  
period of time. The prodrugs may be employed in such  
vaccines either alone or together with other compounds of  
this invention in a manner consistent with the  
conventional utilization of protease inhibitors in  
25 vaccines. For example, a prodrug of this invention may  
be combined with pharmaceutically acceptable adjuvants  
conventionally employed in vaccines and administered in  
prophylactically effective amounts to protect individuals  
over an extended period time against HIV infection. As  
30 such, the novel protease inhibitors of this invention can  
be administered as agents for treating or preventing HIV  
infection in a mammal.

The prodrugs of this invention may be  
administered to a healthy or HIV-infected patient either  
35 as a single agent or in combination with other anti-viral

agents which interfere with the replication cycle of HIV. By administering the compounds of this invention with other anti-viral agents which target different events in the viral life cycle, the therapeutic effect of these compounds is potentiated. For instance, the co-administered anti-viral agent can be one which targets early events in the life cycle of the virus, such as cell entry, reverse transcription and viral DNA integration into cellular DNA. Anti-HIV agents targeting such early life cycle events include, didanosine (ddI), alcitabine (ddC), d4T, zidovudine (AZT), polysulfated polysaccharides, ST4 (soluble CD4), ganciclovir, dideoxycytidine, trisodium phosphonoformate, eflorenithine, ribavirin, acyclovir, alpha interferon and trimenotrexate. Additionally, non-nucleoside inhibitors of reverse transcriptase, such as TIBO or nevirapine, may be used to potentiate the effect of the compounds of this invention, as may viral uncoating inhibitors, inhibitors of trans-activating proteins such as tat or rev, or inhibitors of the viral integrase.

Combination therapies according to this invention exert a synergistic effect in inhibiting HIV replication because each component agent of the combination acts on a different site of HIV replication. The use of such combinations also advantageously reduces the dosage of a given conventional anti-retroviral agent which would be required for a desired therapeutic or prophylactic effect as compared to when that agent is administered as a monotherapy. These combinations may reduce or eliminate the side effects of conventional single anti-retroviral agent therapies while not interfering with the anti-retroviral activity of those agents. These combinations reduce potential of resistance to single agent therapies, while minimizing any associated toxicity. These combinations may also

increase the efficacy of the conventional agent without increasing the associated toxicity. In particular, we have discovered that these prodrugs act synergistically in preventing the replication of HIV in human T cells.

- 5 Preferred combination therapies include the administration of a prodrug of this invention with AZT, ddI, ddC or d4T.

Alternatively, the prodrugs of this invention may also be co-administered with other HIV protease  
10 inhibitors such as Ro 31-8959 (Roche), L-735,524 (Merck), XM 323 (Du-Pont Merck) and A-80,987 (Abbott) to increase the effect of therapy or prophylaxis against various viral mutants or members of other HIV quasi species.

We prefer administering the prodrugs of this  
15 invention as single agents or in combination with retroviral reverse transcriptase inhibitors, such as derivatives of AZT, or other HIV aspartyl protease inhibitors. We believe that the co-administration of the compounds of this invention with retroviral reverse  
20 transcriptase inhibitors or HIV aspartyl protease inhibitors may exert a substantial synergistic effect, thereby preventing, substantially reducing, or completely eliminating viral infectivity and its associated symptoms.

25 The prodrugs of this invention can also be administered in combination with immunomodulators (e.g., bropirimine, anti-human alpha interferon antibody, IL-2, GM-CSF, methionine enkephalin, interferon alpha, diethyldithiocarbamate, tumor necrosis factor, naltrexone  
30 and rEPO); and antibiotics (e.g., pentamidine isethiorate) to prevent or combat infection and disease associated with HIV infections, such as AIDS and ARC.

When the prodrugs of this invention are administered in combination therapies with other agents,  
35 they may be administered sequentially or concurrently to

the patient. Alternatively, pharmaceutical or prophylactic compositions according to this invention may be comprised of a combination of a prodrug of this invention and another therapeutic or prophylactic agent.

5. Although this invention focuses on the use of the prodrugs disclosed herein for preventing and treating HIV infection, the compounds of this invention can also be used as inhibitory agents for other viruses which depend on similar aspartyl proteases for obligatory  
10 events in their life cycle. These viruses include, as well as other AIDS-like diseases caused by retroviruses, such as simian immunodeficiency viruses, but are not limited to, HTLV-I and HTLV-II. In addition, the compounds of this invention may also be used to inhibit  
15 other aspartyl proteases, and in particular, other human aspartyl proteases, including renin and aspartyl proteases that process endothelin precursors.

Pharmaceutical compositions of this invention comprise any of the compounds of the present invention,  
20 and pharmaceutically acceptable salts thereof, with any pharmaceutically acceptable carrier, adjuvant or vehicle. Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not  
25 limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or  
30 electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium  
35 carboxymethylcellulose, polyacrylates, waxes,

polyethylene-polyoxypropylene-block polymers,  
polyethylene glycol and wool fat.

The pharmaceutical compositions of this invention may be administered orally, parenterally, by  
5 inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. We prefer oral administration or administration by injection. The pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable  
10 carriers, adjuvants or vehicles. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.

15 The pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting  
20 agents (such as, for example, Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable  
25 vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed  
30 including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated  
35 versions. These oil solutions or suspensions may also

contain a long-chain alcohol diluent or dispersant such as Ph. Helv or a similar alcohol.

The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, and aqueous suspensions and solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are administered orally, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.

The pharmaceutical compositions of this invention may also be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing a compound of this invention with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components. Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.

Topical administration of the pharmaceutical compositions of this invention is especially useful when the desired treatment involves areas or organs readily accessible by topical application. For application topically to the skin, the pharmaceutical composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier. Carriers for topical administration of the compounds of this invention include, but are not limited

to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical composition can be formulated with a  
5 suitable lotion or cream containing the active compound suspended or dissolved in a carrier. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. The  
10 pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches are also included in this invention.

15           The pharmaceutical compositions of this invention may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline,  
20 employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.

Dosage levels of between about .01 and about  
25 100 mg/kg body weight per day, preferably between about 0.5 and about 50 mg/kg body weight per day of the active ingredient compound are useful in the prevention and treatment of viral infection, including HIV infection. Typically, the pharmaceutical compositions of this  
30 invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single  
35 dosage form will vary depending upon the host treated and



5           Upon improvement of a patient's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of  
10 the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.

As the skilled artisan will appreciate, lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the infection, the patient's disposition to the infection and the judgment of the treating physician.

25           In order that this invention be more fully understood, the following examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way.

30 Example 1

General conditions:


(A) Analytical HPLC 0-100%B/30 min, 1.5 mL/min,  
A=0.1% TFA in water, B=0.1% TFA in acetonitrile.  
Detection at 254 and 220 nm, C18 reverse phase Vydac,  
35 t0=2.4 min.

(B) 1/3 v/v EtOAc/hexane

(C) 1/2 v/v EtOAc/hexane

(D) Analytical HPLC 0-100%B/10 min, 1.5 mL/min,  
A=0.1% TFA in water, B=0.1% TFA in acetonitrile.

5 Detection at 254 and 220 nm, C18 reverse phase Vydac,  
t<sub>0</sub>=2.4 min.




10 A mixture of 2.0g (3.7 mMol) of 197 and 3.0g  
(16 mMol) of di-p-nitrophenyl carbonate in 10 ml of  
dimethylformamide was treated at 25° with 4 ml (4 mMol)  
of P4-phosphazene base (Fluka, 1M in hexane). The  
mixture was stirred for 6h at 25° until all of the  
15 starting alcohol was consumed. The reaction mixture was  
partitioned between ethyl acetate and 1N hydrochloric  
acid. The organic layer was washed with 1N sodium  
hydroxide and brine, dried over magnesium sulfate and  
concentrated in vacuo. Titration with dichloromethane  
20 gave the desired mixed carbonate (1.2g crop1 and 0.6g  
crop 2) as a fine powder. Combined yield: 69%. R<sub>f</sub>=0.13  
(1/3 EtOAc/hexane, conditions B), R<sub>f</sub>=0.40 (1/2  
EtOAc/hexane, conditions C), t<sub>HPLC</sub>=23.83 min (A), MS(ES+)  
701 (M+1).  
25 <sup>1</sup>H-NMR (CDCl<sub>3</sub>): 0.82 (6H,dd), 1.9 (2H,m), 2.15 (1H,m),  
2.8 (1H,m), 3.0 (4H,m), 3.5 (2H,m), 3.6 (1H,m), 3.8  
(4H,m), 4.3 (1H,bs), 4.8 (1H,m), 5.17 (2H,m), 7.7 (7H,m),  
7.95 (2H,d), 8.35 (4H,m).  
<sup>13</sup>C (CDCl<sub>3</sub>): 155.2 152.2, 149.9, 145.6, 135.9, +129.0,  
30 +128.8, +128.5, +127.2, +125.4, +124.4, +121.8, +78.1,

+75.8, -73.1, -66.9, -56.5, +52.7, -48.2, -35.9, -35.9,  
32.6, -+26.4, +19.9, +19.8.

### Example 2

5



To 0.20g (0.286 mM) of 198 dissolved in 3 ml of THF was added 0.11 g (1.14 mM) of 1-Methyl-piperidine and the mixture was stirred overnight at room temperature ("rt"). All the solvents were then evaporated and the solid residue partitioned between EtOAc and water. The volatiles were removed and, where appropriate, the residue was treated with 1:1 TFA/DCM over 30 min at rt to remove the Boc protecting group. The product was dissolved in 0.25 ml TFA and 1.5 ml THF. Hydrogenolysis for 10 hours in presence of 30 mg of 10% Pd/C gave the desired compound. The final purification was on preparative reversed phase C18 using conditions Example 1, except that the flow rate was 18 ml/min.

C,H,N: calc: 49.27, 5.57, 8.25, found 49.15, 5.76, 8.29  
C<sub>31</sub>H<sub>45</sub>N<sub>5</sub>O<sub>7</sub>S<sub>1</sub> · 1.9CF<sub>3</sub>COOH

LC/MS (ES+) 632 (M+1) 1 peak at 4.71 min


Analytical HPLC(A) t=N/A min

1H: 0.71 (3H,d), 0.74 (3H,d), 1.80 (2H,m), 2.03 (1H,m), 2.63 (2H,m), 2.74 (1H,m), 2.82 (3H,s), 2.92 (2H,m), 3.20 (4H,m), 3.42 (3H,m), 3.62 (2H,m), 3.75 (1H,m), 4.05 (3H,m), 4.97 (2H,m), 6.2 (1H,bs), 6.60 (2H,m), 7.22 (5H,m), 7.40 (3H,m),

**This Page Blank (uspto)**

<sup>13</sup>C (DMSO): 156.4, 154.0, 153.8, 138.8, 129.6, 129.5, 128.3, 126.5, 123.7, 112.7, 74.8, 72.9, 66.7, 58.2, 54.0, 53.1, 49.3, 42.3, 40.8, 36.0, 33.3, 25.8, 20.4, 20.3

5

Example 3


The synthesis of compound 200 from compound 198 was carried as described in Example 1, except that N,N-dimethyl-aminoethanol was used in place of di-p-nitrophenyl carbonate.

<sup>1</sup>HNMR (acetone-d<sub>6</sub>): 0.82 (6H, dd), 1.83 (2H, m), 2.07 (1H, m), 2.64 (2H, m), 2.82 (6H, s), 2.90 (2H, m), 3.19 (1H, m), 3.38 (4H, m), 3.63 (2H, m), 3.76 (1H, m), 4.17 (2H, m), 4.40 (1H, m), 4.56 (1H, m), 4.96 (1H, m), 5.06 (1H, m), 6.06 (1H, d), 6.68 (2H, d), 7.23 (5H, m), 7.47 (2H, d).

<sup>13</sup>CNMR (acetone d<sub>6</sub>): 20.2, 20.3, 27.5, 33.4, 35.6, 43.8, 50.1, 54.2, 56.4, 58.5, 63.1, 67.4, 73.6, 76.2, 79.9, 114.2, 118.3, 127.4, 129.2, 130.1, 130.3, 139.3, 153.4, 157.0.

LC/MS: 1 peak, 621 (MH<sup>+</sup>).

25

Example 4

The synthesis of compound 201 from compound 198 was carried as described in Example 1, except that N-acetyl-ethylenediamine was used in place of di-p-nitrophenyl carbonate.

5 C,H,N: calc: 49.66, 5.64, 8.83, found 49.76, 5.98, 8.93

$C_{30}H_{43}N_5O_8S_1 \cdot 1.4CF_3COOH$ ,

LC/MS (ES+) 634 (M+1) 1 peak at 5.08 min.


Analytical HPLC(A) t=15.92 min.

1H: d-3 acetonitrile: 0.88 (6H,dd), 1.92 (3H,s), 1.94  
 10 (2H,m), 2.17 (1H,m), 2.72 (2H,m), 2.96 (2H,m), 3.07  
 (3H,m), 3.29 (1H,m), 3.42 (3H,m), 3.69 (1H,m), 3.77  
 (1H,m), 3.82 (1H,m), 4.133 (1H,m), 4.40 (1H,bs), 5.05  
 (2H,m), 5.80 (1H,m), 6.10 (1H,d), 6.78 (2H,d), 6.83  
 (1H,bs), 7.28 (5H,m), 7.58 (2H,d).

15 <sup>13</sup>C (d3-acetonitrile): 157.1, 157.0, 153.2, 139.6, +130.3,  
 +130.2, +129.2, +127.2, 126.2, +114.2, +76.0, +75.4, -  
 73.6, -67.4, -58.2, +54.9, -50.2, -41.6, -39.8, -35.9, -  
 33.4, +27.3, +23.1, +20.4, +20.2.

20

#### Example 5



The synthesis of compound 202 from compound 198 was carried as described in Example 1, except that mono  
 25 N-Boc-piperazine was used in place of di-p-nitrophenyl carbonate.


C,H,N: calc: 48.28, 5.68, 8.41, found 48.28, 5.36, 8.28

$C_{30}H_{43}N_5O_7S_1 \times 2 CF_3COOH$

LC/MS (ES+) 618 (M+1) 1 peak at 4.36 min.

30 Analytical HPLC(A) t=14.84 min.

1H: d6-DMSO: 0.72 (3H,d), 0.77 (3H,d), 1.78 (2H,m), 2.09 (1H,m), 2.64 (2H,m), 2.73 (1H,m), 2.80 (1H,m), 3.08 (4H,m), 3.32 (2H,m), 3.41 (1H,m), 3.50 (4H,m), 3.54 (1H,m), 3.63 (1H,m), 3.70 (1H,m), 3.98 (1H,m), 4.89 (1H,m), 4.97 (1H,m), 6.61 (2H,d), 7.23 (5H,m), 7.42 (3H,m), 8.88 (2H,bs),  
 13C: (DMSO): 155.7, 153.6, 153.0, 138.4, +129.1, +129.0, +128.1, +126.1, 123.2, +112.7, +75.2, +74.4, -72.5, -66.2, -56.9, +53.1, -48.8, -42.5, -40.8, -35.0, -32.2, +26.2, +20.0, +19.8.

Example 6

The synthesis of compound 203 from compound 198 was carried as described in Example 1, except that mono-N-Boc-ethylenediamine was used in place of di-p-nitrophenyl carbonate.


C,H,N: calc: 46.89, 5.29, 8.54, found 46.50, 5.51, 8.54  
 $C_{28}H_{41}N_5O_7S_1 \times 2 CF_3COOH$ .

LC/MS (ES+) 592 (M+1) 1 peak at 4.32 min.

Analytical HPLC(A) t=14.69 min.

1H:d-6 DMSO: 0.77 (6H,d), 1.82 (2H,m), 2.06 (1H,m), 2.57 (2H,m), 2.82 (4H,m), 2.97 (1H,m), 3.30 (5H,m), 3.55 (1H,m), 3.65 (1H,m), 3.70 (1H,m), 3.95 (1H,m), 4.88 (1H,m), 4.95 (1H,m), 6.62 (2H,d), 7.20 (6H,m), 7.39 (3H,m), 7.78 (3H,bs).

13C (dmso): 155.9, 152.9, 138.5, 129.2, 128.9, 128.1, 126.1, 122.9, 112.7, 74.7, 74.5, 72.6, 66.2, 57.2, 53.2, 49.4, 38.8, 37.94, 35.1, 32.1, 26.3, 20.0, 19.8.

Example 7

5           The synthesis of compound 204 from compound 198 was carried as described in Example 1, except that mono-1,3-diamino-3-N-Boc-propane was used in place of di-p-nitrophenyl carbonate,

C,H,N: calc: 49.07, 5.64, 8.89, found 48.95, 6.00, 8.92


10 C<sub>29</sub>H<sub>43</sub>N<sub>5</sub>O<sub>7</sub>S<sub>1</sub> x 1.6 CF<sub>3</sub>COOH

LC/MS (ES+) 605 (M+1) 1 peak at 4.27 min.

Analytical HPLC(A) t=14.72 min.

1H:d-6 DMSO: 0.78 (6H,dd), 1.64 (2H,m), 1.83 (2H,m), 2.03 (1H,m), 2.57 (1H,m), 2.78 (4H,m), 2.94 (1H,m), 3.03 (2H,m), 3.32 (2H,m), 3.58 (1H,m), 3.63 (1H,m), 3.73 (1H,m), 3.87 (1H,m), 4.84 (1H,m), 4.92 (1H,m), 6.61 (2H,d), 7.22 (6H,m), 7.36 (1H,d), 7.28 (2H,d), 7.76 (3H,ns).

13C (dmso): 155.8, 155.7, 138.5, +129.1, +129.0, +128.0, +126.1, 122.9, +112.7, +74.6, +74.3, -72.7, -66.2, -57.2, +53.6, -49.5, -37.4, -36.7, -35.5, -32.1, -27.6, +26.2, +20.0, +19.8.

Example 8




The synthesis of compound 205 from compound 198 was carried as described in Example 1, except that 1,4-diamino-4-N-Boc-butane was used in place of di-p-nitrophenyl carbonate.

5 C,H,N: calc: 48.17, 5.59, 8.26, found 48.02, 5.96, 8.24  
 $C_{30}H_{45}N_5O_7S_1 \cdot 2 \cdot CF_3COOH$

LC/MS (ES+) 620 (M+1) 1 peak at 4.36 min.

Analytical HPLC(A) t=14.93 min.

1H: d-6 DMSO: 0.77 (6H,dd), 1.43 (4H,m), 1.82 (2H,m),  
 10 2.03 (1H,m), 2.77 (4H,m), 2.95 (3H,m), 3.31 (2H,m), 3.56  
 (1H,m), 3.63 (1H,m), 3.70 (1H,bq), 3.82 (1H,m), 4.85  
 (1H,m), 4.92 (1H,m), 6.62 (2H,d), 7.2 (7H,m), 7.38  
 (2H,d), 7.72 (3H,bs),  
 13C: 155.7, 152.9, +138.6, +129.1, +129.0, +128.0,  
 15 +126.1, +123.0, +112.7, +74.4, +74.3, -72.7, -66.2, -  
 57.2, +53.7, -49.7, -38.6, -38.5, -35.4, -32.1, -26.3,  
 +26.2, -24.4, +20.1, +19.9.



The synthesis of compound 206 from compound 198 was carried as described in Example 1, except that (3R)-(+)-3-Boc-aminopyrrolidine was used in place of di-p-nitrophenyl carbonate.


25 C,H,N: calc: 48.28, 5.36, 8.28, found 47.89, 5.53, 8.57  
 $C_{30}H_{43}N_5O_7S_1 \times 2 \text{ TFA}$

LC/MS (ES+) 618 (M+1) 1 peak at 4.32 min.

Analytical HPLC(A) t=14.31 min.

$^1\text{H}$  and  $^{13}\text{C}$  NMR: complex and overlapping mixtures of rotomers.

47


Example 10

5 The synthesis of compound 207 from compound 198 was carried as described in Example 1, except that (3S)-(-)-3-Boc-aminopyrrolidine was used in place of di-p-nitrophenyl carbonate.

LC/MS (ES+) 618 (M+1) 1 peak at 4.19 min.

Analytical HPLC(A) t=14.75 min.

10 <sup>1</sup>H and <sup>13</sup>C NMR: complex and overlapping mixtures of rotomers.

Example 11

15

The synthesis of compound 308 from compound 198 was carried as described in Example 1, except that N-triphenylmethyl-N,N'-dimethylethanediamine was used in place of di-p-nitrophenyl carbonate.


- 5 1H-NMR: 0.76 (6H,dd), 1.65 (2H,m), 1.95 (1H,m), 2.07 (1H,m), 2.7 (2H,m), 2.75 (3H,s), 2.95 (3H,m), 3.45 (2H,m), 3.7 (4H,m), 4.2 (2H,bm), 5.05 (2H,bd), 6.62 (2H,d), 7.2 (5H,m), 7.5 (2H,d),  
LC/MS: 1 peak, 620 (MH+).

10

### Example 12

#### General Procedures

##### Acylation:




- To 200mg (.37mM) of 197 dissolved in 5ml CH<sub>2</sub>Cl<sub>2</sub> was added N-CBz-L-Benzyl tyrosine 183mg (.41mM) followed by 231 mg (1.12mM) DCC, followed by 29mg (.23mM) DMAP. The reaction is stirred at rt for 24hr. The precipitates  
20 present were removed by filtration. The filtrate was then concentrated in vacuo. The final compound was purified on preparative reversed phase C<sub>18</sub> using purification by HPLC C<sub>18</sub> Waters Delta Prep 3000 Column: YMC-Pack ODS AA 12S05-2520WT 250X20 mm I.D. S-5mm, 120Å, 0-100% B over 1/2h, flow=18 ml/min, monitored at 220 nm,  
25 B=0.1% trifluoroacetic acid in acetonitrile, A=0.1% trifluoroacetic acid in water. Analytical Column: YMC-Pack ODS AA1 2S05-2520WT 250X4.6 mmI.D. S-5mm, 120Å, 0-100% B at 1.5 ml/min. over 1/2 h, monitored at 220 nm,

B=0.1% trifluoroacetic acid in acetonitrile, A=0.1% trifluoroacetic acid in water.


The aqueous phase was lyophilized to give 59 mg, (16.3%) GW431896X, (U11484-72-10). t<sub>HPLC</sub>=11.71 min.,  
 5 MW=966.04, LC/MS=MH+967.

Reduction of the Nitro Functionality:



A slurry of 209 (170 mg) and 10 mg of 10% Pd.C  
 10 in 95% EtOH was flushed with hydrogen in a scintillation vial equipped with septum and a stir bar. Continuous overnight hydrogenolysis under hydrogen balloon resulted in a complete conversion. The crude preparation was then filtered off the catalyst, and purified on RP C18 HPLC  
 15 (Prep Nova-Pack C186 um, 60 A, gradient 0-100% B over 30 min. The desired product was collected and lyophilized affording a white fluffy solid (50 mg, 30.8%).

Example 13




Compound 211 was obtained following the acylation and reduction procedures of Example 12.  
 ES+ 669.2 (M+1), t<sub>HPLC</sub>=8.06 min (D), <sup>13</sup>C NMR (DMSO) 168.9,  
 25 156.9, 155.7, 153.1, 138.1, 130.5, 129.2, 129.1, 128.1,

50

126.2, 124.7, 122.5, 112.8, 76.2, 74.5, 72.5, 66.1, 58.0,  
53.6, 52.6, 49.2, 33.6, 32.1, 26.6, 25.3, 20.0.  
tHPLC=11.71 min (D), ES+ 967 (M+1).

5

Example 14

212 was obtained following the procedures of  
Example 12.

10 tHPLC= 9.45 min (D), ES+ 592.2 (M+1).

13C NMR (DMSO) 171.5, 155.8, 148.9, 137.8, 129.5, 129.3,  
128.5, 126.7, 115.2, 75.2, 73.8, 73.1, 68.3, 67.0, 58.7,  
57.1, 53.3, 49.2, 35.4, 32.4, 26.7, 20.1, 19.8.

1H(CDC13, 399.42 KHz): 8.33 (2H, d, J=8.8), 7.95 (2H, d,  
15 J=8.8), 7.23 (5H, m), 5.22 (m, 2H), 5.08 (m, 1H), 4.08 (m,  
1H), 3.80-3.45 (7H, m), 3.41 (3H, s), 2.98 (m, 3H), 2.66  
(m, 1H), 2.57 (m, 2H), 2.10 (s, 1H), 1.93 (2H, m), 0.82  
(3H, d), 0.78 (3H, d).

ES+ 622 (M+1), 644 (M+Na)


20 tHPLC =10.29 min (D).

13C NMR (CDC13): 171.3, 155.5, 149.9, 145.6, 136.9,  
129.2, 128.6, 128.5, 126.8, 124.4, 76.7, 75.3, 73.2,  
72.9, 68.2, 66.9, 58.7, 55.9, 53.1, 48.3, 35.3, 32.7,  
26.3, 19.9, 19.8.

25

Example 15


51



213 was obtained following the procedure of

- 5 Example 12. tHPLC = 9.21 min (D); ES+ 622 (M+1).  
 13C NMR (CDCl<sub>3</sub>): 170.54, 156.2, 148.6, 136.8, 129.4,  
 129.2, 128.6, 126.6, 115.7, 76.7, 74.6, 73.2, 71.8, 70.6,  
 68.2, 66.9, 58.9, 57.3, 53.8, 49.4, 36.2, 33.1, 26.8,  
 19.8, 19.5.
- 10 Intermediate: t HPLC = 10.05 min (D); ES+= 652 (M+H) 674 (M+Na).

#### Example 16




214 was obtained following the procedure of  
 Example 12.

- ES+ 634.4 (M+1); t HPLC = 7.17 min (D).  
 13C (DMSO): 169.3, 155.8, 153.1, 138.0, 129.1, 129.0,  
 20 128.1, 126.3, 122.6, 112.8, 94.3, 75.6, 74.6, 72.4, 66.1,  
 57.8, 52.7, 52.0, 49.3, 38.4, 34.7, 32.2, 29.1, 26.6,  
 21.4, 20.1, 20.0.

#### Example 17

52




215 was obtained following the procedure of Example 12.

- 5 t HPLC = 9.12 min (D)  
 1H (DMSO) all signals broad: 7.38 (3H, br m), 7.20 (5H, br m), 6.62 (2H, br m), 5.15 (1H, br m), 4.92 (1H, br m), 4.00 (3H, m), 3.7-3.0 (16H, m), 2.78 (2H, m), 2.57 (3H, m), 2.04 (m, 1H), 1.78 (m, 2H), 0.77 (6H, m)  
 10 13C (DMSO) 170.6, 156.3, 153.7, 139.1, 129.8, 128.4, 126.7, 123.7, 113.3, 79.8, 79.2, 77.3, 76.1, 75.4, 75.2, 73.0, 71.9, 52.3, 51.8, 48.2, 46.7, 39.9, 38.7, 25.8, 22.6.

Intermediate:

- 15 t HPLC = 10.18 min (D); ES+ 696.3 (M+1).

#### Example 18




- 20 216 was obtained following the procedure of Example 12.

- 1H-NMR: 0.97 (6H, t), 1.95 (2H, m), 2.20 (1H, m), 2.9 (2H, m), 2.96 (6H, s), 3.00 (3H, s), 3.38 (1H, m), 3.42 (3H, m), 3.36 (1H, m), 3.6 (2H, m), 3.7 (6H, m), 3.98 (2H, m),  
 25 4.2 (2H, dd), 5.1 (1H, bs), 5.4 (1H, m), 6.8 (2H, d), 7.4 (5H, m), 7.6 (2H, d).



LC-MS: 1 peak, 692 (MH+).


Example 19



217 was obtained following the procedure of Example 12.

1H-NMR (CDCl<sub>3</sub>): 0.78 (6H,dd), 1.9 (2H,m), 2.1 (1H,m), 2.3 (3H,s), 2.9 (8H,m), 2.9 (2H,m), 3.15 (1H,m), 3.35 (1H,m), 3.5 (1H,m), 3.75 (4H,m), 4.06 (2H,s), 4.15 (2H,m), 4.9 (1H,dd), 5.05 (1H,bs), 5.2 (1H,bs), 6.63 (2H,d), 7.2 (5H,m), 7.55 (2H,d), 8.0 (2H,m).

ESMSP: 676 (MH+).

Example 20General Procedure for N-acylated Compounds

5           A mixture of 0.5g (1 mMol) of (3S)-Tetrahydro-3-furfuryl-N-((1S,2R)-1-benzyl-2-hydroxy-3-(N-isobutyl-4-aminobenzenesulfonamido)propyl) carbamate, 0.4g (1.5 mMol) of Boc-(S)-3-pyridyl alanine, 0.29g (1.5 mMol) EDCI and 0.1g 4-dimethylamino pyridine in 10 ml of N,N-

10 dimethylformamide was stirred at 25° for 12 hours. The volatiles were removed in vacuo and the residue was partitioned between ethyl acetate and 1N hydrochloric acid. The organic layer was washed with 1N sodium hydroxide and brine, dried over magnesium sulfate and

15 concentrated in vacuo. The residue was chromatographed on a 2 inch plug of silica gel (1:1 ethyl acetate: hexane) to give the desired N-acylated material. Deprotection by treatment with 50 ml of trifluoroacetic acid, followed by co-evaporation of residual acid with

20 methanol gave the desired prodrug as a white foam (0.2g, 26%).


H1-NMR (acetonitrile-D3): 0.95 (6H,dd), 2.0 (2H,m), 2.25 (1h,m), 2.8-3.1 (5H,m), 3.6-4.0 (7H,m), 4.25 (1H,m), 4.75 (1H,m), 5.18 (1H,m), 5.45 (1H,m), 7.0 (2H,d), 7.4 (5H,m),

25 7.75 (2H,d), 8.2 (1H,m), 8.8 (1H,d), 8.85 (1H,d), 9.15 (1H,s).

LC/MS: 1 peak, 654 (MH+).

Example 21

55




220 was obtained using the general procedure in

5 Example 20.

<sup>1</sup>H-NMR (acetone-d<sub>6</sub>/ methanol-d<sub>4</sub>): 0.95 (6H,t), 2.0 (2H,m), 2.2 (1H,m), 2.90 (1H,dd), 2.95 (2H,d), 3.12 (1H,dd), 3.4 (2H,m), 6 (1H,d), 3.8 (5H,m), 4.4 (2H,bm), 6.82 (2H,d), 7.20 (1H,s), 7.4 (5H,m), 7.65 (2H,d), 8.0 (1H,s).

10 LC/MS: 1 peak, 643 (MH<sup>+</sup>).

#### Example 22



15

221 was obtained using the general procedure in Example 20.


20 <sup>1</sup>H-NMR (DMSO d-6): 0.76 (6H,t), 1.80 (2H,m), 2.10 (1H,m), 3.7 (4H,m), 3.75 (3H,s), 3.2 (5H,m), 3.58 (2H,s), 3.7 (4H,m), 4.97 (1H,bm), 5.18 (1H,bs), 6.7 (2H,d), 7.22 (5H,m), 7.45 (2H,d).

LC/MS: 1 peak, 646 (MH<sup>+</sup>).

25

#### Example 23


56



222 was obtained using the general procedure in Example 20.

5 <sup>1</sup>H NMR (acetonitrile d-3): 1.0 (6H, t), 2.0 (2H, m), 2.2 (1H, m), 3.00 (6H, s), 3.02 (3H, s), 3.1 (4H, m), 3.5 (3H, m), 3.8 (8H, m), 4.4 (2H, s), 5.15 (1H, bs), 7.4 (5H, m), 7.97 (2H, d), 8.04 (2H, d),  
 LC/MS: 1 peak, 692 (MH<sup>+</sup>).

10

Example 24

223 was obtained using the general procedure in


15 Example 20.

t HPLC = 9.22 min (D); ES<sup>+</sup> 622 (M+1).

<sup>1</sup>H NMR d6-DMSO: 0.76 (6H, dd), 1.0-1.8 (15H, m), 2.03 (1H, m), 2.58 (2H, m), 2.79 (2H, m), 3.11 (1H, m), 3.28 (3H, s), 3.3-3.5 (12H, m), 3.94 (1H, m), 4.08 (1H, m), 4.94 (1H, m), 5.14 (1H, m), 6.61 (2H, d), 7.22 (5H, m), 7.40 (3H, m).  
<sup>13</sup>C (DMSO) 169.7, 165.9, 152.9, 138.4, 129.2, 129.1, 128.1, 126.2, 123.1, 112.8, 74.4, 74.1, 72.5, 71.2, 69.8,

57

66.1, 58.1, 57.1, 52.9, 47.5, 33.4, 33.2, 26.3, 24.5,  
18.9, 18.8.


Example 25

224 was obtained using the general procedure in Example 20.

Example 26O,N-diacylated Prodrugs

The general procedure for N,O-diacylated compounds followed the protocol outlined in Example 20, above, except that a five fold excess of reagents was used relative to the starting material.

15




t HPLC 9.26 min (D); ES+ 738 (M+1) 760 (M+Na).

<sup>13</sup>C (DMSO): 170.2, 169.8, 156.4, 143.4, 138.8, 129.5,  
128.8, 128.5, 126.8, 119.7, 74.9, 74.2, 73.7, 71.6, 70.7,  
70.3, 68.0, 67.2, 59.3, 57.6, 53.8, 49.6, 35.7, 33.8,  
27.1, 20.4.

<sup>1</sup>H (DMSO): 10.1 (1H, s), 7.84 (d, 2H, J=8.5), 7.76 (d, J=8.7, 2H), 7.40 (1H, d, J=9.2), 7.22 (m, 5H), 5.14 (1H,


m), 4.95 (1H, m), 4.1 (m, 8H), 3.7-3.3 (m, 13H), 3.28 (s, 3H), 3.26 (s, 3H), 2.86 (m, 2H), 2.73 (m, 1H), 2.59 (m, 1H), 2.04 (m, 1H), 1.83 (m, 2H), 0.78 (m, 6H).

5

Example 27

To a mixture of 197 (2.93 g, 5.47 mmol) and  
 10 phosphorous acid (Aldrich, 2.2 equiv., 12.03 mmol, 987  
 mg) in 20 ml pyridine was added 1,3-  
 dicyclohexylcarbodiimide (Aldrich, 2.1 equiv., 11.49  
 mmol, 2.37 g) and the reaction heated to 60 °C under  
 nitrogen for 3h. Solvent was removed *in vacuo*, the  
 15 residue treated with 200 ml 0.1N aqueous sodium  
 bicarbonate and stirred 1h at ambient temperature. The  
 mixture was filtered, the filtrate acidified to pH 1.5 by  
 addition of conc. HCl and extracted with ethyl acetate (3  
 x 100 ml). The combined organic layers were dried over  
 20 magnesium sulfate, filtered and concentrated *in vacuo* to  
 give 3.15g (96%) of desired product 226 which was used  
 directly in the next reaction. HPLC: Rt = 8.91 min  
 (96%), MS (AP+) 600.5 (M+1).

25

Example 28


A suspension of 226 (~5.47 mmol) in 18 ml hexamethyldisilazane was stirred at 120°C until homogeneous followed by addition of bis(trimethylsilyl) peroxide (Gelest, Inc., 2.3 equiv., 12.58 mmol, 2.24 g, 2.71 ml). After 1h the mixture was cooled to ambient temperature, solvent removed *in vacuo*, the residue stirred with 100 ml methanol, solvent removed *in vacuo*, the residue stirred with 100 ml 0.1N aqueous sodium bicarbonate, acidified to pH 1.5 by addition of conc. HCl, saturated with brine and extracted with ethyl acetate (3 x 100 ml). The combined organic layers were dried over magnesium sulfate, filtered and concentrated *in vacuo* to give 2.98 g (88%) of desired product 227, which was used directly in the next reaction. HPLC: Rt = 9.28 min (90%), MS (AP+) 616.5 (M+1).

Alternatively, 227 can be synthesized directly from 197. In this method, 197 was dissolved in pyridine (300mL). The resulting solution was concentrated *in vacuo* to about 150 ml at 50-55°C. The solution was then cooled under N<sub>2</sub> to 5°C, and treated with POCl<sub>3</sub> (6.5 ml, 1.24 equiv.) over 2 minutes. The cooling bath was removed and the reaction stirred at ambient temperature for 2.5 hrs. The solution was then cooled to 5°C and water (300 ml) was added over 30 minutes.

The resulting mixture was extracted with 4-methylpentan-2-one (MIBK, 2 x 150 ml). The combined extracts were washed with 2N HCl (2 x 250 ml). The acid washes were back extracted with MIBK (60 ml), then the combined MIBK solutions were treated with 2N HCl (150 ml). The two phase mixture was stirred rapidly and heated to 50°C for 2 hours. The reaction mixture was cooled to 20°C, the phases were separated and the MIBK solution was washed with brine (150 ml). The product, 227, was isolated by drying the solution with magnesium sulfate, filtering of the drying agent and concentrating


in vacuo at 40°C to give the product as a pale yellow foam (31 g, 90% yield).

### Example 29



10 A solution of 227 (2.98 g, 4.84 mmol) in 50 ml ethyl acetate was treated with 10% palladium on carbon (Aldrich, 300 mg) and put under 35 psi of hydrogen on a Parr shaker for 15h. Catalyst was removed by filtration and solvent removed *in vacuo* to give 2.66 g (94%) of desired product 228. HPLC: Rt = 7.23 min (92%), MS (ES+) 586.3 (M+1).

### Example 30




20 Solid 228 (2.66 g, 4.54 mmol) was treated with 10 ml aqueous sodium bicarbonate (Baker, 3.0 equiv., 13.63 mmol, 1.14 g) and loaded onto a resin column (Mitsubishi Kasei Corp., MCI-gel, CHP-20). Distilled water was run through until the eluent was neutral followed by product elution with 1% acetonitrile in water. Pure fractions were pooled and lyophilized to give 918 mg of pure bis-sodium salt 229.

25

### Example 31

30





5

0.53 g (3.0 mmol) 2-[2-(2-Methoxyethoxy)ethoxy] acetic acid was added to a stirred solution of 1.2 g (3.15 mmol) HATU 0.2 g (1.47 mmol) HOAt 0.4 g (4.0 mmol) NMM in 10 ml anhydrous N,N-dimethylformamide. The mixture was stirred at room temperature for 30 minutes, then 0.5 g (1 mmol) of (3S)-Tetrahydro-3-furfuryl-N-((1S,2R)-1-benzyl-2hydroxy-3-(N-isobutyl-4-aminobenzenesulfonamido)-propyl) carbamate was added to the solution in one portion. The mixture was stirred at 20°C for an hour then at 50°C for an additional 12 hours. It was then cooled to 20°C, 50 ml of ether was added, and the solution was washed with water three times. The aqueous phase was washed with ether, and then the combined organic phases were dried with anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel chromatography to obtain the desired Mono-(N)acylated (102 mg, 15 %) and Bis-(O,N) acylated (262 mg, 32%) compounds.

Mono-(N)-acylated: <sup>1</sup>H-NMR(CDCl<sub>3</sub>): 0.85 (dd, 6H), 1.85 (m, 2H), 2.08 (m, 1H), 2.8-3.1 (m, 7H), 3.33 (s, 3H), 3.55 (m, 3H), 3.70-3.90 (m, 8H), 4.1 (s, 2H), 5.0 (d, 1H), 5.08 (s(br), 1H), 7.2 (m, 5H), 7.70 (d, 2H), 7.80 (d, 2H), 9.09 (s, 1H).


MS(FAB<sup>+</sup>): 666 (M+1).

Bis-(O,N)-acylated: <sup>1</sup>H-NMR(CDCl<sub>3</sub>): 0.77 (m, 6H), 1.81 (m, 1H), 1.95 (m, 1H), 2.05 (m, 1H), 2.6-3.0 (m, 6H), 3.2 (m, 1H), 3.332 (s, 3H), 3.338 (s, 3H), 3.5-3.8 (m, 18H), 4.1 (s, 2H), 4.14 (s, 2H), 4.17 (m, 1H), 5.05 (m, 2H),

5.25 (s(br), 1H), 7.2 (m, 5H), 7.69 (d, 2H), 7.78 (d 2H), 9.06 (s, 1H).

MS (FAB+): 826 (M+1), 848 (M+Na).

5

Example 32

We dissolved 0.521g (1 mM) of 1273W94 in 5 ml THF, then cooled to  $-78^{\circ}\text{C}$  under nitrogen, and added 1.56 ml (2.5 mM) of a 1.6 M solution of nBuLi in hexane. After 20 min at  $-78^{\circ}\text{C}$ , we added 105  $\mu\text{L}$  (1.1 mM) of ethyl chlorocarbamate and warmed up the reaction to room temperature, followed by addition of another 105  $\mu\text{L}$  of ethyl chlorocarbamate.

20 After stirring for additional 4 hrs, the reaction was quenched with water and the organic solvent evaporated. Part of the crude product was purified on a silica gel ( $R_f=0.69$  (1:2 ethyl acetate:hexane)), yielding 0.131g of the product.

25 C,H,N: calc: 46.06, 4.97, 5.88, found 45.90, 4.97, 5.88  
 $\text{C}_{23}\text{H}_{33}\text{N}_5\text{O}_5\text{S}_1$ . 2.2 TFA


LC/MS (ES+) 594 (M+1) 1 peak at 6.96 min.

Analytical HPLC(A)  $t=24.57$  min.

13C (CDCl<sub>3</sub>): 155.8, 154.4, 149.9, 145.7, 136.8, +129.2, +128.7, +126.8, +124.2, 80.1, +76.9, -64.3, -56.2, -52.5, -48.7, -36.2, +28.1, +26.4, +20.0, +19.8, +14.3.

30

63

Example 33233


We dissolved 0.131g of the above ethyl  
 5 carbonate in 4 ml DCM, followed by 4 ml of TFA. Solvents  
 were then removed after 45 min at room temperature,  
 resulting in the title compound.

1H (DMSO): 8.37 (2H, d, J=7.2), 8.15 (2H, m), 8.00 (2H,  
 d, J=7.0), 7.37 (5H, m), 5.04 (1H, d, J=6.9), 4.06 (2H,  
 10 q, J=7.0), 3.82 ((1H, m), 3.35 (2H, m), 2.95 (4H, m),  
 1.82 (1H, m), 1.20 (3H, t, J=7.0), 0.72 (overlapping  
 doublets, 6H, J=6.2).

LC/MS 1 peak at 4.76 min.

ES+ 497.3 (M+1).

15

Example 34O,N-Acyloxy Rearrangement233234


20 C,H,N: calc: 53.26, 6.14, 7.57, found 53.22, 6.14, 7.57

C<sub>23</sub>H<sub>33</sub>N<sub>5</sub>O<sub>5</sub>S<sub>1</sub> x 0.8 TFA

LC/MS (ES+) 594 (M+1) 1 peak at 6.96 min.

Analytical HPLC(A) t=24.57 min.

1H (DMSO): 8.34 (2H, d, J=8.7), 8.02 (2H, d, J=8.0), 7.19 (5H, m), 6.98 (1H, d, J=7.2), 5.00 (1H, m), 3.83 (2H, q), 3.50 (2H, m), 3.06 (m, 2H), 2.96 (2H, m), 2.43 (1H, m), 1.97 (1H, m), 1.02 (3H, t), 0.84 (3H, d), 0.82 (3H, d).  
 5 13C (DMSO): 156.2, 150.1, 145.7, 140.0, +129.7, +129.2, +128.5, +126.3, +125.0, +71.8, -60.0, +56.2, -56.0, -51.8, -36.0, +26.3, +20.3, +20.1, +14.6.

Example 35

10

235


Synthesis of 235 was accomplished analogous to that set forth in Example 1.

Yield 15.2%; tHPLC=25.2 min (A).

15 Rf=0.54 (B); ES+ 687.3 (M+1).

1H (CDCl3): 8.34 (overlapping d+d, 4H), 7.97 (d, 2H, J=8.9), 7.35 (7H, m), 5.09 (1H, m), 4.56 (1H, d, J=8.4), 4.20 (1H, m), 3.54 (1H, m), 3.00 (3H, m), 2.82 (1H, m), 1.84 (1H, m), 1.37 (9H, s), 0.84 (3H, d), 0.82 (3H, d).

20

Example 36236


We dissolved 150 mg of 235 in 3 ml of anhydrous dioxane, added 0.35 ml of S(+)-3-OH-THF and 0.14 ml triethyl amine. The mixture was refluxed gently under nitrogen for 2 days. Conversion to 236 was quantitative.

- 5 Solvents were removed and the compound purified on silica (B).

tHPLC=22.98 min (A); ES+ 636.2 (M+1).

- 1H NMR (CDCl<sub>3</sub>): 8.29 (2H, d), 7.91 (2H, d), 7.22 (5H, m),  
5.13 (1H, m), 4.96 (1H, m), 4.52 (1H, d), 4.02 (1H, m),  
10 3.84 (2H, m), 3.44 (1H, m), 3.36 (1H, m), 3.10 (3H, m,  
overlap), 2.88 (2H, m), 2.64 (1H, m), 2.14 (1H, m), 2.05  
(1H, m), 1.84 (1H, m), 1.27 (9H, s), 0.78 (6H, two overl.  
d).

Example 37  
Carbohydrate-Based Prodrugs



- 5
- 10
- 15
- A mixture of 0.54g (1 mMol) of (3S)-Tetrahydro-3-furfuryl-N-((1S,2R)-1-benzyl-2-hydroxy-3-(N-isobutyl-4-aminobenzenesulfonamido)propyl) carbamate, 0.46g (2 mMol) of 5-dimethyl-tert-butyrosilyloxypentanoic acid, 0.346g (1.8mMol) of EDCI and 0.556mL (4 mMol) of triethylamine in 10 ml of dimethyl formamide was stirred at rt for 24h. Another 3 mMol each of acid, EDCI and triethylamine were added and stirring was continued for an additional 96h. A third batch of acid and EDCI was added (3 mMol each) and the mixture was stirred 72h to complete the reaction.

The reaction mixture was then diluted with ethyl acetate and extracted with 1N hydrochloric acid, saturated sodium bicarbonate and water. Evaporation of

the solvent and purification on silica gel (30% ethyl acetate-hexane) gave the desired product (500mg) as a waxy solid.

LCMS: 1 peak, 772.5 (M+Na)

5    1H NMR (CDCl<sub>3</sub>): 0.01 (6H,s), 0.78 (6H,dd), 0.95 (9H,s),  
1.4-1.8 (6H,m), 1.9 (2H,m), 2.05 (1H,m), 2.3 (2H,m), 2.65  
(1H,m), 2.95 (2H,m), 3.22 (1H,m), 3.4 (1H,m), 3.6 (2H,m),  
3.75 (3H,m), 4.8 (1H,d), 5.1 (1H,bs), 5.2 (1H,bs), 7.2  
(5H,m), 7.95 (2H,d), 8.36 (2H,d).


10            450mg of the 238 was dissolved in 30 ml of tetrahydrofuran and treated with 20 ml of water and 50 ml of acetic acid. The mixture was stirred at rt for 2h and evaporated. Titration with hexane gave the desired alcohol (290mg) as a white solid.

15            A mixture of 0.15g (0.24 mMol) of the alcohol produced above from the previous reaction, 0.205g (0.5 mMol) of tetraacetylglucosylbromide and 0.191g (0.7 mMol) of silver carbonate in 3 ml of dichloromethane was stirred at rt for 6h. 150mg of additional glucosyl  
20 bromide and 150 mg of silver carbonate were added and the mixture was stirred at rt overnight. The mixture was loaded onto a pad of silica gel and eluted with 30% ethylacetate-hexane to afford the desired protected carbohydrate pro-drug as a white foam (200mg).

25    LCMS: 1 peak, 966 (M+H).  
1H-NMR (CDCl<sub>3</sub>): 0.78 (6H,dd), 1.9 (2H,m), 2.00 (3H,s),  
2.02 (3H,s), 2.05 (3H,s), 2.06 (3H,s), 2.1 (2H,m), 2.3  
(2H,m), 2.7 (1H,m), 2.94 (3H,bd), 3.35 (2H,m), 3.45  
(2H,m), 3.8 (5H,m), 4.1 (3H,m), 4.5 (1H,d), 4.9 (1H,bs),  
30 4.95 (1H,t), 5.08 (4H,m), 2H,d), 8.35 (2H,d).

#### Example 38


68

197239

1.5 g (9.4 mmol) SO<sub>3</sub>.py complex was added to a stirred solution of 1 g (1.87 mmol) of 197 in 25 mL anhydrous tetrahydrofuran. The mixture was stirred at 20°C for 12 hours, then filtered. The filtrate was concentrated at reduced pressure, and the residue was transferred to a silica gel column and eluted with EtOAc (neat), followed by EtOAc:EtOH (4:1) to obtain 471 mg (47 %) 239 as a colorless foam.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>): 0.80 (m, 6H), 1.8-2.1 (m, 3H), 4.15 (s(br), 1H), 4.8 (t, 1H), 5.04 (s (br), 1H).

MS(ES<sup>-</sup>): 614 (M-1).

239240


15

100 mg (0.162 mmol) 239 dissolved in 15 ml anhydrous tetrahydrofuran and 200 mg Pd/BaSO<sub>4</sub> (5%) was added to the solution. The mixture was stirred under atmospheric pressure of hydrogen for 8 hours, and then the catalyst was filtered. The filtrate was concentrated under reduced pressure then dried under vacuum (~1 Hg mm, 48 hrs.) to produce 80 mg (81 %) 240 as a colorless foam.

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): 0.85 (dd, 6H), 0.90 (m, 1H), 2.05 (m, 2H), 2.58 (m, 3H), 2.84 (dd, 1H), 3.05 (m, 2H), 3.55-3.80 (m, 6H), 4.20 (t, 1H), 4.42 (m, 1H), 4.93 (s(br), 1H), 6.09 (s, 2H), 6.70 (d, 2H), 6.80 (d, 1H), 7.15-7.40 (m, 4H), 7.51 (d, 2H).

MS(ES<sup>-</sup>): 584 (M-1).



Example 39

- 5                    780 mg (3 mmol) 2-Chloro-1,3,2-dioxaphospholane  
 was added to a stirred solution of 1.07 g (2 mmol) 197  
 and 0.7 ml (4 mmol) N,N-Diisopropylethylamine in 25 ml  
 dichloromethane at 0°C. The mixture was allowed to warm  
 up to room temperature and it was stirred for 2 hours.
- 10 The mixture was then cooled to 0°C and 1.5 g (9.3 mmol)  
 bromine was added in 5 ml dichloromethane. The mixture  
 was stirred for 1 hour at 20°C, followed by evaporation  
 under reduced pressure. An aqueous solution (50%) of 15  
 ml trimethylamine was added to the residue, and the
- 15 mixture was stirred at 20 °C for 12 hours.


Solvents were removed under reduced pressure  
 and 50 ml EtOAc:EtOH (9:1) was added to the residue. The  
 solid was filtered, washed with EtOAc:EtOH (9:1) then the  
 filtrate was concentrated under reduced pressure. The

20 residue was chromatographed on a 3 inch plug of silica  
 gel using ethyl acetate (neat), then methanol (neat), as  
 eluents to obtain 1.15 g (82 %) 241 as an off-white  
 solid.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>): 0.60 (dd, 6H), 1.70 (m, 1H), 1.95 (m, 1H),  
 25 2.10 (m, 1H), 2.8-3.2 (m, 6H), 3.4 (s (br), 9H), 5.09  
 (s(br), 1H), 7.25 (m, 5H), 7.83 (d, 2H), 8.28 (d, 2H).  
 MS(ES<sup>+</sup>): 701 (M+1), 184 (phosphatidyl choline+).

Example 40


70



250 mg Pd/C (10 %) was added to a solution of 250 mg (0.35 mmol) 241 in 10 ml methanol, and the mixture was stirred under atmospheric pressure of hydrogen for 4 hours at 20°C. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was then dissolved in 10 ml water and lyophilized to obtain 174 mg (74 %) 242 as white solid.

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): 0.82 (dd, 6H), 1.80-2.00 (m, 2H), 2.10 (m, 1H), 2.80 (m, 3H), 3.00 (m, 2H), 3.2 (s (br), 9H), 4.0-4.3 (m, 4H), 4.91 (s(br), 1H), 6.08 (s(br), 2H), 6.67(d, 2H), 7.30 (m, 5H), 7.48 (d, 2H), 8.12 (d, 1H). MS(ES<sup>+</sup>): 671 (M+1), 184 (phosphatidyl choline<sup>+</sup>).

#### Example 41



0.175 ml (2 mmol) phosphorus trichloride was added to a stirred solution of 1.07 g (2 mmol) 197 and 0.35 ml (2 mmol) N,N-Diisopropylethylamine in 25 ml dichloromethane at 20°C. The mixture was stirred for 4 hours at 20°C, then 1 ml water was added and stirred for an additional 12 hours at 20°C. 3 g anhydrous magnesium

sulfate was added to the mixture and it was stirred for 30 minutes, then filtered. The filtrate was concentrated under reduced pressure and purified by silica gel chromatography using EtOAc:Hexane (4:1), then EtOAc:EtOH

(1:1), to obtain 402 mg (48%) 226 and 427 mg (36%) 243.


226:

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): 0.82 (dd, 6H), 1.84 (m, 1H), 1.98 (m, 1H), 2.10 (m, 1H), 2.68 (dd, 1H), 2.9-3.2 (m, 4H), 3.6-3.8 (m, 3H), 3.94 (t, 1H), 4.30, (s(br), 1H), 4.97 (s(br), 1H), 7.30 (m, 5H), 8.14 (d, 2H), 8.43 (d, 2H).  
MS(ES<sup>-</sup>): 598 (M-1).

243: (1:1 mix of diastereomers):

<sup>1</sup>H-NMR(CDCl<sub>3</sub>): 0.80 (m, 6H), 1.8-2.1 (m, 4H), 2.8-3.2 (m, 6H), 3.7-3.9 (m, 4H), 4.15 (m, 1H), 4.8-5.15 (m, 2H), 5.57, 5.72 ((d,d), 1H), 7.25 (m, 5H), 7.95 (dd, 2H), 8.35 (m, 2H).  
MS(ES<sup>-</sup>): 580 (M-1), 598 ((M+H<sub>2</sub>O)-1).


#### Example 42



The reduction was carried out as described in Example 40; (Yield: 79%).

<sup>1</sup>H-NMR(DMSO-d<sub>6</sub>): 0.81 (dd, 6H), 1.82 (m, 1H), 1.95 (m, 1H), 2.08 (m, 1H), 2.6-3.15 (m, 6H), 3.6-3.75 (m, 3H), 4.03 (t, 1H), 4.28, (m, 1H), 4.96 (s(br), 1H), 6.07 (s, 2H), 6.65 (d, 2H), 7.25 (m, 5H), 7.42 (d, 2H).  
MS(ES<sup>-</sup>): 568 (M-1).

72



The reduction was carried out as described in Example 40; (Yield: 98 %).

- 5 (1:1 mix of diastereomers):  
 1H-NMR(DMSO-d<sub>6</sub>): 0.82 (m, 6H), 1.75-2.0 (m, 2H), 2.05 (m, 1H), 2.6-3.2 (m, 6H), 3.55-3.8 (m, 4H), 4.02, 4.22 (m, t, 1H), 4.75 (m, 1H), 4.90, 5.01 ((d,d), 1H), 6.12 (s, 1H), 6.68 (d, 2H), 7.30 (m, 5H), 7.49 (d, 2H).  
 10 MS(ES<sup>-</sup>): 550 (M-1), 568 ((M+H<sub>2</sub>O)-1).

#### Example 44

##### Pharmacokinetics In Sprague-Dawley Rats Following Single Oral Dose

15

In order to study the pharmacokinetics of the prodrugs of this invention, we administered single oral doses of a series of prodrugs of this invention, as well as VX-478, to male and female Sprague-Dawley rats.

- 20 Administration of molar equivalents of a series of prodrugs of this invention in a variety of pharmaceutical vehicles was tested.

Separate groups of male and female Sprague-Dawley rats (3/sex/group) received oral doses of compound 229 by oral gavage, in different vehicles at the same dose equivalent (40 mg/kg molar equivalent of VX-478). The different vehicles for compound 229 were: 1) water; 2) 5/4/1; 3) PEG 400; 4) TPGS/PEG 400; and 5) PEG. The vehicles for VX-478 were: 1) 33% TPGS/PEG400/PEG; and 2) 30 12.5 % TPGS/PEG 400/PEG.

Blood samples were collected following administration at various time intervals and analyzed for the presence of both compound 229 and its metabolite, VX-478, by HPLC and MS methods. The results of this study are tabulated below (Table IV).

TABLE IV

Compound	229	229	229	229	VX-478	VX-478
vehicle	H <sub>2</sub> O	H <sub>2</sub> O:PG:E tOH 5:4:1	PEG 400	TPGS/P EG 400/PG	33% TPGS/ PEG 400/ PG	12.5% TPGS/ PEG 400/PG
number of rats	3	3	3	3	6	23
Molar equiv. dose/ 478 Dose (mg/Kg)	40 PO	40 PO	40 PO	40 PO	41 PO	50 PO
AUC (ug*hr/ml)	11.7 $\pm$ 4.8	10.6 $\pm$ 7.4	7.4 $\pm$ 1.8	8.2 $\pm$ 1.6	29.6 $\pm$ 5.8	16.2 $\pm$ 1.8
Cmax ( $\mu$ M)	7.1 $\pm$ 1.7	3.3 $\pm$ 0.6	3.1 $\pm$ 0.3	3.0 $\pm$ 0.7	14.0 $\pm$ 2.2	6.0 $\pm$ 1.0
half life (hr)	1.7*	3.4*	2.8*	2.8*	2.5 $\pm$ 0.9	2.2 $\pm$ 1.0
Relative Avail. of VX- 478	39.5 $\dagger$ 90.2 $\dagger\dagger$	35.8 $\dagger$ 81.8 $\dagger\dagger$	25.0 $\dagger$ 57.1 $\dagger$ $\dagger$	27.7 $\dagger$ 63.3 $\dagger\dagger$	reference	reference

- a dose of 50 mg / Kg of compound 229 is equal to 40 mg/ Kg of VX-478.

- no compound 229 was detected in plasma at 15 min. ( first data point ).

\* Represents the harmonic mean

† Relative availability of VX-478 when compared to a  
5 prototype clinical formulation

†† Relative availability of VX-478 when compared to a prototype  
toxicology formulation

10 We performed a similar study on dogs using both  
a solid capsule formulation of compound 229 and an  
ethanolic/methyl cellulose solution formulation, as  
compared to a TPGS-containing solution formulation of VX-  
478. The results from this study are presented below in  
Table V.

15

TABLE V

Compound	229	229	VX-478
vehicle	solid capsule	methyl cellulose in 5% EtOH/water	22% TPGS/PEG 400/PG
number of dogs	2	2	>2
Molar equiv. dose/ 478 Dose (mg/Kg)	17 PO	17 PO	17 PO
AUC (ug*hr/ml)	16.7 ± 2.7	14.2 ± 3.2	23.5 ± 7.4
Cmax (ug/ml)	6.1 ± 1.7	6.3 ± 0.3	6.8 ± 1.1
Tmax (hr)	2.3 ± 0.6	0.5 ± 0.5	1.0 ± 0.8
Relative Avail. of VX-478 (%)	71.1	60.4	reference

The results demonstrate that oral administration of compound 229 as an aqueous solution resulted in improved bioavailability in comparison to the other vehicles studied. Also, following administration of compound 229, none of that compound was detected in the first time point blood sample (or later samples), suggesting first pass metabolism to VX-478. Comparison of the aqueous dose of compound 229 with the two non-aqueous formulations used for VX-478 indicated equivalence in delivery as illustrated by the range found for the bioavailability.


While we have described a number of embodiments of this invention, it is apparent that our basic constructions may be altered to provide other embodiments which utilize the products and processes of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims, rather than by the specific embodiments which have been presented by way of example.

CLAIMS

We claim:

1. A compound of formula I:

5



(I)

wherein:

- each R<sup>1</sup> is independently selected from the group  
 10 consisting of C(O)-, -S(O)<sub>2</sub>-, -C(O)-C(O)-, -O-C(O)-, -O-S(O)<sub>2</sub>, -NR<sup>2</sup>-S(O)<sub>2</sub>-, -NR<sup>2</sup>-C(O)- and -NR<sup>2</sup>-C(O)-C(O)-;

- each A is independently selected from the group  
 consisting of 5-7 membered monocyclic heterocycles  
 containing from 1-3 endocyclic heteroatoms, which may be  
 15 optionally methylated at the point of attachment,  
 optionally benzofused, optionally attached through a C<sub>1</sub>-C<sub>3</sub>  
 alkyl linker and optionally fused with a 5-7 membered  
 monocyclic heterocycle containing from 1-2 endocyclic  
 heteroatoms, and wherein unmethylated THF is expressly  
 20 excluded;

- each Ht is independently selected from C<sub>3</sub>-C<sub>7</sub>  
 cycloalkyl; C<sub>5</sub>-C<sub>7</sub> cycloalkenyl; C<sub>6</sub>-C<sub>10</sub> aryl; or a 5-7  
 membered saturated or unsaturated heterocycle, containing  
 one or more heteroatoms selected from N, N(R<sup>2</sup>), O, S and  
 25 S(O)<sub>n</sub>; wherein said aryl or said heterocycle is optionally  
 fused to Q; and wherein any member of said Ht is  
 optionally substituted with one or more substituents  
 independently selected from oxo, -OR<sup>2</sup>, SR<sup>2</sup>, -R<sup>2</sup>, -



$N(R^2)(R^2)$ ,  $-R^2-OH$ ,  $-CN$ ,  $-CO_2R^2$ ,  $-C(O)-N(R^2)_2$ ,  $-S(O)_2-N(R^2)_2$ ,  
 $-N(R^2)-C(O)-R^2$ ,  $-C(O)-R^2$ ,  $-S(O)_n-R^2$ ,  $-OCF_3$ ,  $-S(O)_n-Q$ ,  
methylenedioxy,  $-N(R^2)-S(O)_2(R^2)$ , halo,  $-CF_3$ ,  $-NO_2$ ,  $Q$ ,  $-OQ$ ,  
 $-OR^7$ ,  $-SR^7$ ,  $-R^7$ ,  $-N(R^2)(R^7)$  or  $-N(R^7)_2$ ;

5 each  $Q$  is independently selected from a 3-7  
membered saturated, partially saturated or unsaturated  
carbocyclic ring system; or a 5-7 membered saturated,  
partially saturated or unsaturated heterocyclic ring  
containing one or more heteroatoms selected from  $O$ ,  $N$ ,  $S$ ,  
10  $S(O)_n$  or  $N(R^2)$ ; wherein  $Q$  is optionally substituted with  
one or more groups selected from oxo,  $-OR^2$ ,  $-R^2$ ,  $-N(R^2)_2$ ,  
 $-N(R^2)-C(O)-R^2$ ,  $-R^2-OH$ ,  $-CN$ ,  $-CO_2R^2$ ,  $-C(O)-N(R^2)_2$ , halo or  
 $-CF_3$ ;

each  $R^2$  is independently selected from the group  
15 consisting of  $H$  and  $C_1-C_3$  alkyl optionally substituted  
with  $Q$ ;

each  $x$  is independently 0 or 1;

each  $R^3$  is independently selected from the group  
consisting of  $H$ ,  $Ht$ ,  $C_1-C_6$  alkyl and  $C_2-C_6$  alkenyl wherein  
20 any member of said  $R^3$ , except  $H$ , may be optionally  
substituted with one or more substituents selected from  
the group consisting of  $-OR^2$ ,  $-C(O)-NH-R^2$ ,  $-S(O)_n-$   
 $N(R^2)(R^2)$ ,  $Ht$ ,  $-CN$ ,  $-SR^2$ ,  $-CO_2R^2$ ,  $NR^2-C(O)-R^2$ ;

each  $n$  is independently 1 or 2;

25  $G$ , when present, is selected from  $H$ ,  $R^7$  or  $C_1-C_4$   
alkyl, or, when  $G$  is  $C_1-C_4$  alkyl,  $G$  and  $R^7$  are bound to one  
another either directly or through a  $C_1-C_3$  linker to form  
a heterocyclic ring; or

when  $G$  is not present (i.e., when  $x$  in  $(G)_x$  is  
30 0), then the nitrogen to which  $G$  is attached is bound  
directly to the  $R^7$  group on  $-OR^7$ ;

each  $D$  and  $D'$  is independently selected from  
the group consisting of  $Q$ ;  $C_1-C_5$  alkyl, which may be  
optionally substituted with one or more groups selected  
35 from  $C_3-C_6$  cycloalkyl,  $-OR^2$ ,  $-R^3$ ,  $-O-Q$ ,  $-S-Q$  and  $Q$ ;  $C_2-C_4$

alkenyl, which may be optionally substituted with one or more groups selected from the group consisting of C<sub>3</sub>-C<sub>6</sub> cycloalkyl, -OR<sup>2</sup>, R<sup>3</sup>, O-Q and Q; C<sub>3</sub>-C<sub>6</sub> cycloalkyl, which may be optionally substituted with or fused with Q; and  
 5 C<sub>5</sub>-C<sub>6</sub> cycloalkenyl, which may be optionally substituted with or fused with R<sup>6</sup>;


each E is independently selected from the group consisting of Ht; -O-Ht; Ht-Ht; -O-R<sup>3</sup>; -NR<sup>2</sup>R<sup>3</sup>; C<sub>1</sub>-C<sub>6</sub> alkyl, which may be optionally substituted with one or more  
 10 groups selected from the group consisting of R<sup>4</sup> and Ht; and C<sub>2</sub>-C<sub>6</sub> alkenyl, which may be optionally substituted with one or more groups selected from the group consisting of R<sup>4</sup> and Ht; C<sub>3</sub>-C<sub>6</sub> saturated carbocycle, which is optionally substituted with one or more groups  
 15 selected from R<sup>4</sup> or Ht; or C<sub>5</sub>-C<sub>6</sub> unsaturated carbocycle, which is optionally substituted with one or more groups selected from R<sup>4</sup> or Ht;

each R<sup>4</sup> is independently selected from the group consisting of OR<sup>2</sup>, -C(O)-NHR<sup>2</sup>, S(O)<sub>2</sub>-NHR<sup>2</sup>, halo, NR<sup>2</sup>-C(O)-R<sup>2</sup> and -CN;

each R<sup>5</sup> is independently selected from the group consisting of H and C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with aryl; and

each R<sup>6</sup> is independently selected from the group  
 25 consisting of aryl, carbocycle and heterocycle, wherein said aryl, carbocycle or heterocycle may be optionally substituted with one or more groups selected from the group consisting of oxo, -OR<sup>5</sup>, -R<sup>5</sup>, N(R<sup>5</sup>)(R<sup>5</sup>), N(R<sup>5</sup>)-C(O)-R<sup>5</sup>, -R<sup>5</sup>-OH, -CN, CO<sub>2</sub>R<sup>5</sup>, C(O)-N(R<sup>5</sup>)(R<sup>5</sup>), halo and CF<sub>3</sub>;

30 each R<sup>7</sup> is independently selected from



35 wherein each M is independently selected

from H, Li, Na, K, Mg, Ca, Ba,  $-N(R^2)_4$ ,  $C_1$ - $C_{12}$ -alkyl,  $C_2$ - $C_{12}$ -alkenyl,  $-R^6$ ; wherein 1 to 4  $-CH_2$  radicals of the alkyl or alkenyl group, other than the  $-CH_2$  that is bound to Z, is optionally replaced by a heteroatom group selected  
 5 from O, S,  $S(O)$ ,  $S(O)_2$ , or  $N(R^2)$ ; and wherein any hydrogen in said alkyl, alkenyl or  $R^6$  is optionally replaced with a substituent selected from oxo,  $-OR^2$ ,  $-R^2$ ,  $N(R^2)_2$ ,  $N(R^2)_3$ ,  $R^2OH$ ,  $-CN$ ,  $-CO_2R^2$ ,  $-C(O)-N(R^2)_2$ ,  $S(O)_2-N(R^2)_2$ ,  $N(R^2)-C(O)-R_2$ ,  $C(O)R^2$ ,  $-S(O)_n-R^2$ ,  $OCF_3$ ,  $-S(O)_n-R^6$ ,  $N(R^2)-S(O)_2(R^2)$ , halo,  $-$   
 10  $CF_3$ , or  $-NO_2$ ;

$M'$  is H,  $C_1$ - $C_{12}$ -alkyl,  $C_2$ - $C_{12}$ -alkenyl,  $-R^6$ ; wherein 1 to 4  $-CH_2$  radicals of the alkyl or alkenyl group is optionally replaced by a heteroatom group selected  
 15 from O, S,  $S(O)$ ,  $S(O)_2$ , or  $N(R^2)$ ; and wherein any hydrogen in said alkyl, alkenyl or  $R^6$  is optionally replaced with a substituent selected from oxo,  $-OR^2$ ,  $-R^2$ ,  $-N(R^2)_2$ ,  $N(R^2)_3$ ,  $-R^2OH$ ,  $-CN$ ,  $-CO_2R^2$ ,  $-C(O)-N(R^2)_2$ ,  $-S(O)_2-N(R^2)_2$ ,  $-N(R^2)-C(O)-R_2$ ,  $-C(O)R^2$ ,  $-S(O)_n-R^2$ ,  $-OCF_3$ ,  $-S(O)_n-R^6$ ,  $-N(R^2)-S(O)_2(R^2)$ , halo,  $-CF_3$ , or  $-NO_2$ ;

20  $Z$  is O, S,  $N(R^2)_2$ , or, when M is absent, H;  
 $Y$  is P or S;  
 $X$  is O or S; and  
 $R^9$  is  $C(R^2)_2$ , O or  $N(R^2)$ ; and wherein when Y is S, Z is not S; and

25  $R^6$  is a 5-6 membered saturated, partially saturated or unsaturated carbocyclic or heterocyclic ring system, or an 8-10 membered saturated, partially saturated or unsaturated bicyclic ring system; wherein  
 30 any of said heterocyclic ring systems contains one or more heteroatoms selected from O, N, S,  $S(O)_n$  or  $N(R^2)$ ; and wherein any of said ring systems optionally contains 1 to 4 substituents independently selected from OH,  $C_1$ - $C_4$  alkyl, O- $C_1$ - $C_4$  alkyl or  $OC(O)C_1$ - $C_4$  alkyl.



3. The compound according to claim 1, wherein D is benzyl.

4. The compound according to claim 3, wherein  
5 A is selected from 3-(1,5-dioxane)-O-C(O)-, or 3-hydroxy-hexahydrofura[2,3-b]-furanyl-O-C(O)-;

D' is (C<sub>1</sub>-C<sub>4</sub>)-alkyl which is optionally substituted with one or more groups selected from the group consisting of (C<sub>3</sub>-C<sub>6</sub>)-cycloalkyl, -OR<sup>2</sup>, -R<sup>3</sup>, -O-Q and Q;

10 E is (C<sub>6</sub>-C<sub>10</sub>)-aryl optionally substituted with one or more substituents selected from oxo, -OR<sup>2</sup>, SR<sup>2</sup>, -R<sup>2</sup>, -N(R<sup>2</sup>)<sub>2</sub>, -R<sup>2</sup>-OH, -CN, -C(O)O-R<sup>2</sup>, -C(O)-N(R<sup>2</sup>)<sub>2</sub>, -S(O)<sub>2</sub>-N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)-C(O)-R<sup>2</sup>, -C(O)-R<sup>2</sup>, -S(O)<sub>n</sub>-R<sup>2</sup>, -OCF<sub>3</sub>, -S(O)<sub>n</sub>-Q, methylenedioxy, -N(R<sup>2</sup>)-S(O)<sub>2</sub>-R<sup>2</sup>, halo, -CF<sub>3</sub>, -NO<sub>2</sub>, Q, -OQ,  
15 -OR<sup>7</sup>, -SR<sup>7</sup>, -R<sup>7</sup>, -N(R<sup>2</sup>)(R<sup>7</sup>) or -N(R<sup>7</sup>)<sub>2</sub>; or a 5-membered heterocyclic ring containing one S and optionally containing N as an additional heteroatom, wherein said heterocyclic ring is optionally substituted with one to two groups independently selected from -CH<sub>3</sub>, R<sup>4</sup>, or Ht;  
20 and

Ht, insofar as it is defined as part of R<sup>3</sup>, is defined as in claim 1 except for the exclusion of heterocycles.

25 5. The compound according to claim 4 wherein A is 1,3-dioxanyl.

6. The compound according to claim 5 wherein  
A is 1,3-dioxan-5-yl.

30

7. The compound according to claim 4, wherein:

G is hydrogen;

D' is isobutyl;

35 E is phenyl substituted with N(R<sup>7</sup>)<sub>2</sub>;

each M is independently selected from H, Li, Na, K, Mg, Ca, Ba, C<sub>1</sub>-C<sub>4</sub> alkyl or -N(R<sup>2</sup>)<sub>4</sub>; and  
each M' is H or C<sub>1</sub>-C<sub>4</sub> alkyl.

5                    8. The compound according to claim 3,  
wherein:

E is a 5-membered heterocyclic ring containing one S and optionally containing N as an additional heteroatom, wherein said heterocyclic ring is optionally substituted  
10 with one to two groups independently selected from -CH<sub>3</sub>, R<sup>4</sup>, or Ht.

9. The compound according to claim 3,  
wherein:

15 E is Ht substituted with N(R<sup>7</sup>)<sub>2</sub>;  
R<sup>7</sup> in the -OR<sup>7</sup> group is -PO(OM)<sub>2</sub> or C(O)CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub> and both R<sup>7</sup> in the -N(R<sup>7</sup>)<sub>2</sub> substituent of Ht are H; or R<sup>7</sup> in -OR<sup>7</sup> group shown in formula XXII is C(O)CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, one R<sup>7</sup> in the -N(R<sup>7</sup>)<sub>2</sub>  
20 substituent of Ht is C(O)CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub> and the other R<sup>7</sup> in the -N(R<sup>7</sup>)<sub>2</sub> substituent of Ht is H; and  
wherein M is H, Li, Na, K or C<sub>1</sub>-C<sub>4</sub> alkyl.

10. The compound according to claim 3, wherein  
25 R<sup>7</sup> in the -OR<sup>7</sup> group is -PO(OM)<sub>2</sub> or -C(O)-M' and M is Na or K.

11. The compound according to claim 2,  
wherein:

30 R<sup>3</sup> is (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>5</sub>-C<sub>6</sub>)-cycloalkyl, (C<sub>5</sub>-C<sub>6</sub>)-cycloalkenyl, or a 5-6 membered saturated or unsaturated heterocycle; wherein any member of R<sup>3</sup> is optionally substituted with one or more substituents selected from the group consisting of -OR<sup>2</sup>, -

$C(O)-NH-R^2$ ,  $-S(O)_nN(R^2)_2$ ,  $-Ht$ ,  $-CN$ ,  $-SR^2$ ,  $-C(O)O-R^2$  and  $N(R^2)-C(O)-R^2$ ; and

D' is  $(C_1-C_3)$ -alkyl or  $C_3$  alkenyl; wherein D' is optionally substituted with one or more groups selected from  $(C_3-C_6)$ -cycloalkyl,  $-OR^2$ ,  $-O-Q$  or  $Q$ .

12. The compound according to claim 11, wherein  $R^7$  in the  $-OR^7$  group is  $-PO(OM)_2$  or  $-C(O)-M'$ .

10 13. A pharmaceutical composition, comprising a compound according to any one of claims 1 to 12 in an amount effective to treat infection by a virus that is characterized by an aspartyl protease; and a pharmaceutically acceptable carrier, adjuvant or vehicle.

15 14. The pharmaceutical composition according to claim 13, wherein said virus is HIV.

20 15. The pharmaceutical composition according to claim 13, wherein said pharmaceutical composition is formulated for oral administration.

25 16. The pharmaceutical composition according to claim 13, further comprising one or more agents selected from an anti-viral agent, an HIV protease inhibitor other than a compound according to claim 1, and an immunostimulator.

30 17. The pharmaceutical composition according to claim 16, further comprising one or more agents selected from zidovudine (AZT), zalcitabine (ddC), didanosine (ddI), stavudine (d4T), 3TC, 935U83, 1592U89, 524W91, saquinavir (Ro 31-8959), L-735,524, SC-52151, ABT 538 (A80538), AG 1341, XM 412, XM 450, CPG 53,437, or  
35 tuscarasol.

18. A method for inhibiting aspartyl protease activity in a mammal, comprising the step of contacting administering to said mammal a pharmaceutical composition according to claim 13.

19. A method for treating HIV infection in a mammal comprising the step of administering to said mammal a pharmaceutical composition according to claim 13.

20. The method according to claim 19, wherein said mammal is additionally administered one or more additional agents selected from an anti-viral agent, an HIV protease inhibitor other than a compound according to claim 1, and an immunostimulator either as a part of a single dosage form with said pharmaceutical composition or as a separate dosage form.

21. The method according to claim 20, wherein said additional agent is selected from zidovudine (AZT), zalcitabine (ddC), didanosine (ddI), stavudine (d4T), 3TC, 935U83, 1592U89, 524W91, saquinavir (Ro 31-8959), L-735,524, SC-52151, ABT 538 (A80538), AG 1341, XM 412, XM 450, CPG 53,437, or tuscarasol.

22. The method according to claim 19, wherein said step of administering comprises oral administration.



**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> C07D 319/06, 317/24, 493/04, 309/12, 307/20, C07F 9/09, A61K 31/335, 31/66, 31/70		<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 99/33793</b> <b>(43) International Publication Date:</b> 8 July 1999 (08.07.99)
<b>(21) International Application Number:</b> PCT/US98/27424 <b>(22) International Filing Date:</b> 23 December 1998 (23.12.98) <b>(30) Priority Data:</b> 60/068,889 24 December 1997 (24.12.97) US <b>(71) Applicant (for all designated States except US):</b> VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 130 Waverly Street, Cambridge, MA 02139-4242 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> HALE, Michael, R. [US/US]; 42 Sunset Road, Bedford, MA 01730 (US). TUNG, Roger, D. [US/US]; 54 Richfield Road, Arlington, MA 01274 (US). BAKER, Christopher, T. [US/US]; Apartment 5, 23 Judith Lane, Waltham, MA 02154 (US). SPALTENSTEIN, Andrew [US/US]; 4105 Brewster Drive, Raleigh, NC 27606 (US). FURFINE, Eric, Steven [US/US]; 4133 Livingstone Place, Durham, NC 27707 (US). KALDOR, Istvan [US/US]; 7 Bonham Court, Durham, NC 27703 (US). KAZMIERSKI, Wieslaw, Mieczyslaw [US/US]; 1221 Stone Creek Way, Raleigh, NC 27615 (US). <b>(74) Agents:</b> HALEY, James, F., Jr.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US) et al.		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> <b>(88) Date of publication of the international search report:</b> 10 September 1999 (10.09.99)	
<b>(54) Title:</b> PRODRUGS OF ASPARTYL PROTEASE INHIBITORS			
<b>(57) Abstract</b> <p>The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile <i>in vivo</i> generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 98/27424

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D319/06 C07D317/24 C07D493/04 C07D309/12 C07D307/20  
C07F9/09 A61K31/335 A61K31/66 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D C07F A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 33187 A (VERTEX PHARMACEUTICALS INC) 24 October 1996 cited in the application see page 15, line 14 - page 16, line 2; table I; claims ---	1,13-22
A	WO 95 06030 A (G.D. SEARLE & CO ET AL) 2 March 1995 see page 244, lines 26-38; claims ---	1,13-22
A	WO 94 05639 A (VERTEX PHARMACEUTICALS INC) 17 March 1994 see tables I-IV; page 79, lines 7-16; claims 1-10, 16-24 & US 5 585 397 A (R.D. TUNG ET AL) cited in the application --- -/--	1,13-22

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

31 May 1999

Date of mailing of the international search report

15/07/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Van Amsterdam, L

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/27424

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	S. SAWADA ET AL: CURR. PHARM. DES., vol. 1, no. 1, 1995, pages 113-132, XP002104269 see page 120, figure 7 -----	1,2
A	J.M. BALKOVEC ET AL: J. MED. CHEM., vol. 35, no. 1, 1992, pages 194-198, XP002104270 see page 195, table I -----	1,2

## INTERNATIONAL SEARCH REPORT

international application No.

PCT/US 98/ 27424

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 18-22  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 18-22  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

In tional Application No

PCT/US 98/27424

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9633187 A	24-10-1996	US 5691372 A AU 5665596 A BG 102041 A BR 9608033 A CA 2217745 A CN 1184474 A CZ 9703294 A EP 0833826 A NO 974744 A NZ 307342 A PL 322904 A SK 143097 A ZA 9602891 A	25-11-1997 07-11-1996 30-09-1998 12-01-1999 24-10-1996 10-06-1998 18-03-1998 08-04-1998 14-10-1997 29-04-1999 02-03-1998 04-03-1998 15-10-1996
WO 9506030 A	02-03-1995	US 5843946 A AT 174587 T AU 7669794 A DE 69415326 D EP 0715618 A ES 2127938 T US 5830897 A US 5786483 A US 5744481 A	01-12-1998 15-01-1999 21-03-1995 28-01-1999 12-06-1996 01-05-1999 03-11-1998 28-07-1998 28-04-1998
WO 9405639 A	17-03-1994	AP 390 A AT 178598 T AU 691160 B AU 4852093 A BG 99540 A CA 2143208 A CN 1087347 A CZ 9500587 A DE 69324369 D EP 0659181 A EP 0885887 A FI 951059 A HU 71892 A JP 8501299 T LT 917 A, B NO 950876 A NZ 256238 A NZ 314376 A PL 307858 A SG 43862 A SK 29395 A US 5585397 A US 5783701 A US 5723490 A US 5856353 A	02-08-1995 15-04-1999 14-05-1998 29-03-1994 30-11-1995 17-03-1994 01-06-1994 13-12-1995 12-05-1999 28-06-1995 23-12-1998 18-04-1995 28-02-1996 13-02-1996 25-11-1994 08-05-1995 24-04-1997 28-10-1998 26-06-1995 14-11-1997 13-09-1995 17-12-1996 21-07-1998 03-03-1998 05-01-1999

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**This Page Blank (uspto)**